Movatterモバイル変換

[0]ホーム
URL:

ES2503743T3 - Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN - Google Patents

Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARNDownload PDF

Info

Publication number
ES2503743T3
ES2503743T3ES10183543.7TES10183543TES2503743T3ES 2503743 T3ES2503743 T3ES 2503743T3ES 10183543 TES10183543 TES 10183543TES 2503743 T3ES2503743 T3ES 2503743T3
Authority
ES
Spain
Prior art keywords
seq
mir
hsa
mmu
rno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10183543.7T
Other languages
English (en)
Inventor
David Brown
Lance Ford
Angie Cheng
Rich Jarvis
Mike Byrom
Dmitriy Ovcharenko
Eric Devroe
Kevin Kelnar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asuragen Inc
Original Assignee
Asuragen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=37570916&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2503743(T3)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Asuragen IncfiledCriticalAsuragen Inc
Application grantedgrantedCritical
Publication of ES2503743T3publicationCriticalpatent/ES2503743T3/es
Activelegal-statusCriticalCurrent
Anticipated expirationlegal-statusCritical

Links

Classifications

Landscapes

Abstract

Una molécula de ácido nucleico miARN sintético que comprende una secuencia con una identidad de secuencia de al menos el 80% con la secuencia del miR-126 maduro humano para su uso en la terapia de un cáncer.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
E10183543
17-09-2014
Tabla 1
Secuencias miARN Humano
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
hsa-mir-1-2
SEC ID Nº 1 53-73
hsa-mir-1-1
SEC ID Nº 2 46-66
hsa-let-7a-1
SEC ID Nº 3 6-27
hsa-let-7a-2
SEC ID Nº 4 5-26
hsa-let-7a-3
SEC ID Nº 5 4-25
hsa-let-7b
SEC ID Nº 6 6-27
hsa-let-7c
SEC ID Nº 7 11-32
hsa-let-7d
SEC ID Nº 8 8-28
hsa-let-7e
SEC ID Nº 9 8-28
hsa-let-7f-1
SEC ID Nº 10 7-28
hsa-let-7f-2
SEC ID Nº 11 8-29
hsa-mir-7-1
SEC ID Nº 12 24-44
hsa-mir-7-2
SEC ID Nº 13 32-52
hsa-mir-7-3
SEC ID Nº 14 31-51
hsa-let-7g
SEC ID Nº 15 5-25
hsa-let-7i
SEC ID Nº 16 6-24
hsa-mir-9-1
SEC ID Nº 17 16-38 y/o 56-76
hsa-mir-9-2
SEC ID Nº 18 16-38 y/o 54-74
hsa-mir-9-3
SEC ID Nº 19 16-38 y/o 56-76
hsa-mir-10a
SEC ID Nº 20 22-44
hsa-mir-10b
SEC ID Nº 21 27-48
hsa-mir-15a
SEC ID Nº 22 14-35
hsa-mir-15b
SEC ID Nº 23 20-41
hsa-mir-16-1
SEC ID Nº 24 14-35
hsa-mir-16-2
SEC ID Nº 25 10-31
hsa-mir-17
SEC ID Nº 26 14-37 y/o 51-70
hsa-mir-18
SEC ID Nº 27 6-27
hsa-mir-19a
SEC ID Nº 28 49-71
hsa-mir-19b-1
SEC ID Nº 29 54-76
hsa-mir-19b-2
SEC ID Nº 30 62-84
hsa-mir-20
SEC ID Nº 31 8-29
hsa-mir-21
SEC ID Nº 32 8-29
has-mir-22
SEC ID Nº 33 53-74
hsa-mir-23a
SEC ID Nº 34 45-65
hsa-mir-23b
SEC ID Nº 35 58-80
hsa-mir-24-1
SEC ID Nº 36 6-28 y/o 44-65
11
E10183543
17-09-2014
(Continuación)
Secuencias miARN Humano
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
hsa-mir-24-2
SEC ID Nº 37 50-71
hsa-mir-25
SEC ID Nº 38 52-73
hsa-mir-26a-1
SEC ID Nº 39 10-31
hsa-mir-26b
SEC ID Nº 40 12-32
hsa-mir-26a-2
SEC ID Nº 41 14-35
hsa-mir-27a
SEC ID Nº 42 51-72
hsa-mir-27b
SEC ID Nº 43 61-80
hsa-mir-28
SEC ID Nº 44 14-35
hsa-mir-29a
SEC ID Nº 45 41-62
hsa-mir-29b-1
SEC ID Nº 46 51-70
hsa-mir-29b-2
SEC ID Nº 47 52-71
hsa-mir-29c
SEC ID Nº 48 54-75
hsa-mir-30a
SEC ID Nº 49 47-68
hsa-mir-30c-2
SEC ID Nº 50 7-29
hsa-mir-30d
SEC ID Nº 51 6-27
hsa-mir-30b
SEC ID Nº 52 17-37
hsa-mir-30c-1
SEC ID Nº 53 17-39
hsa-mir-30e
SEC ID Nº 54 2-21
hsa-mir-31
SEC ID Nº 55 9-29
hsa-mir-32
SEC ID Nº 56 6-26
hsa-mir-33
SEC ID Nº 57 6-24
hsa-mir-34a
SEC ID Nº 58 22-43
hsa-mir-34b
SEC ID Nº 59 14-35
hsa-mir-34c
SEC ID Nº 60 13-34
hsa-mir-92-1
SEC ID Nº 61 48-69
hsa-mir-92-2
SEC ID Nº 62 48-69
hsa-mir-93
SEC ID Nº 63 12-33
hsa-mir-95
SEC ID Nº 64 49-70
hsa-mir-96
SEC ID Nº 65 9-30
hsa-mir-98
SEC ID Nº 66 2-23
hsa-mir-99a
SEC ID Nº 67 13-34
hsa-mir-99b
SEC ID Nº 68 7-28
hsa-mir-100
SEC ID Nº 69 13-34
hsa-mir-101-1
SEC ID Nº 70 47-68
12
E10183543
17-09-2014
(Continuación)
Secuencias miARN Humano
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
hsa-mir-101-2
SEC ID Nº 71 49-70
hsa-mir-103-2
SEC ID Nº 72 48-70
hsa-mir-103-1
SEC ID Nº 73 48-70
hsa-mir-105-1
SEC ID Nº 74 13-32
hsa-mir-105-2
SEC ID Nº 75 13-32
hsa-mir-106a
SEC ID Nº 76 13-36
hsa-mir-106b
SEC ID Nº 77 12-32
hsa-mir-107
SEC ID Nº 78 50-72
hsa-mir-122a
SEC ID Nº 79 15-37
hsa-mir-124a-1
SEC ID Nº 80 52-73
hsa-mir-124a-2
SEC ID Nº 81 61-82
hsa-mir-124a-3
SEC ID Nº 82 52-73
hsa-mir-125b-1
SEC ID Nº 83 15-36
hsa-mir-125a
SEC ID Nº 84 15-37
hsa-mir-125b-2
SEC ID Nº 85 17-38
hsa-mir-126
SEC ID Nº 86 15-35 y/o 52-72
hsa-mir-127
SEC ID Nº 87 57-78
hsa-mir-128a
SEC ID Nº 88 50-71
hsa-mir-128b
SEC ID Nº 89 52-73
hsa-mir-129-2
SEC ID Nº 90 15-35
hsa-mir-130a
SEC ID Nº 91 55-74
hsa-mir-130b
SEC ID Nº 92 51-72
hsa-mir-132
SEC ID Nº 93 59-80
hsa-mir-133a-1
SEC ID Nº 94 54-75
hsa-mir-133a-2
SEC ID Nº 95 60-81
hsa-mir-133b
SEC ID Nº 96 67-87
hsa-mir-134
SEC ID Nº 97 8-28
hsa-mir-135a-1
SEC ID Nº 98 17-39
hsa-mir-135a-2
SEC ID Nº 99 23-45
hsa-mir-135b
SEC ID Nº 100 16-37
hsa-mir-136
SEC ID Nº 101 15-37
hsa-mir-137
SEC ID Nº 102 60-81
hsa-mir-138-2
SEC ID Nº 103 10-26
hsa-mir-138-1
SEC ID Nº 104 23-39
hsa-mir-139
SEC ID Nº 105 7-24
13
E10183543
17-09-2014
(Continuación)
Secuencias miARN Humano
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
hsa-mir-140
SEC ID Nº 106 24-44
hsa-mir-141
SEC ID Nº 107 60-80
hsa-mir-142
SEC ID Nº 108 16-35 y/o 52-74
hsa-mir-143
SEC ID Nº 109 61-82
hsa-mir-144
SEC ID Nº 110 52-73
hsa-mir-145
SEC ID Nº 111 16-39
hsa-mir-146
SEC ID Nº 112 21-42
hsa-mir-147
SEC ID Nº 113 47-66
hsa-mir-148a
SEC ID Nº 114 44-65
hsa-mir-148b
SEC ID Nº 115 63-84
hsa-mir-149
SEC ID Nº 116 15-36
hsa-mir-150
SEC ID Nº 117 16-37
hsa-mir-151
SEC ID Nº 118 46-67
hsa-mir-152
SEC ID Nº 119 54-74
hsa-mir-153-1
SEC ID Nº 120 54-73
hsa-mir-153-2
SEC ID Nº 121 53-72
hsa-mir-154
SEC ID Nº 122 15-36
hsa-mir-155
SEC ID Nº 123 4-25
hsa-mir-181a
SEC ID Nº 124 39-61
hsa-mir-181b-1
SEC ID Nº 125 36-59
hsa-mir-181c
SEC ID Nº 126 27-48
hsa-mir-181b-2
SEC ID Nº 127 16-39
hsa-mir-182
SEC ID Nº 128 23-44 y/o 67-87
hsa-mir-183
SEC ID Nº 129 27-49
hsa-mir-184
SEC ID Nº 130 53-74
hsa-mir-185
SEC ID Nº 131 15-32
hsa-mir-186
SEC ID Nº 132 15-37
hsa-mir-187
SEC ID Nº 133 71-91
hsa-mir-188
SEC ID Nº 134 15-36
hsa-mir-190
SEC ID Nº 135 15-36
hsa-mir-191
SEC ID Nº 136 16-37
hsa-mir-192
SEC ID Nº 137 24-44
hsa-mir-193
SEC ID Nº 138 55-75
hsa-mir-194-1
SEC ID Nº 139 15-36
hsa-mir-194-2
SEC ID Nº 140 15-36
14
E10183543
17-09-2014
(Continuación)
Secuencias miARN Humano
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
hsa-mir-195
SEC ID Nº 141 15-35
hsa-mir-196-1
SEC ID Nº 142 7-27
hsa-mir-196-2
SEC ID Nº 143 25-45
hsa-mir-197
SEC ID Nº 144 48-69
hsa-mir-198
SEC ID Nº 145 6-24
hsa-mir-199a-1
SEC ID Nº 146 6-28 y/o 46-67
hsa-mir-199a-2
SEC ID Nº 147 31-53 y/o 69-90
hsa-mir-199b
SEC ID Nº 148 26-48
hsa-mir-200b
SEC ID Nº 149 54-77
hsa-mir-200c
SEC ID Nº 150 45-66
hsa-mir-200a
SEC ID Nº 151 54-75
hsa-mir-203
SEC ID Nº 152 65-86
hsa-mir-204
SEC ID Nº 153 33-54
hsa-mir-205
SEC ID Nº 154 34-55
hsa-mir-206
SEC ID Nº 155 53-74
hsa-mir-208
SEC ID Nº 156 44-65
hsa-mir-210
SEC ID Nº 157 66-86
hsa-mir-211
SEC ID Nº 158 26-47
hsa-mir-212
SEC ID Nº 159 71-91
hsa-mir-213
SEC ID Nº 160 24-46 y/o 64-85
hsa-mir-214
SEC ID Nº 161 71-91
hsa-mir-215
SEC ID Nº 162 27-47
hsa-mir-216
SEC ID Nº 163 19-39
hsa-mir-217
SEC ID Nº 164 35-58
hsa-mir-218-1
SEC ID Nº 165 25-45
hsa-mir-218-2
SEC ID Nº 166 25-45
hsa-mir-219-1
SEC ID Nº 167 21-41
hsa-mir-219-2
SEC ID Nº 168 19-39
hsa-mir-220
SEC ID Nº 169 23-43
hsa-mir-221
SEC ID Nº 170 65-87
hsa-mir-222
SEC ID Nº 171 69-92
hsa-mir-223
SEC ID Nº 172 68-88
hsa-mir-224
SEC ID Nº 173 8-30
hsa-mir-296
SEC ID Nº 174 14-34
hsa-mir-299
SEC ID Nº 175 7-28
15
E10183543
17-09-2014
(Continuación)
Secuencias miARN Humano
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
hsa-mir-301
SEC ID Nº 176 51-73
hsa-mir-302
SEC ID Nº 177 44-66
hsa-mir-320
SEC ID Nº 178 48-70
hsa-mir-321
SEC ID Nº 179 10-30
hsa-mir-323
SEC ID Nº 180 50-71
hsa-mir-324
SEC ID Nº 181 16-38 y/o 51-72
hsa-mir-326
SEC ID Nº 182 60-79
hsa-mir-328
SEC ID Nº 183 48-69
hsa-mir-330
SEC ID Nº 184 57-79
hsa-mir-331
SEC ID Nº 185 61-81
hsa-mir-335
SEC ID Nº 186 16-38
hsa-mir-337
SEC ID Nº 187 56-78
hsa-mir-338
SEC ID Nº 188 42-64
hsa-mir-339
SEC ID Nº 189 15-35
hsa-mir-340
SEC ID Nº 190 58-80
hsa-mir-342
SEC ID Nº 191 61-84
hsa-mir-345
SEC ID Nº 573 17-37
hsa-mir-346
SEC ID Nº 574 4-26
hsa-mir-367
SEC ID Nº 575 44-65
hsa-mir-368
SEC ID Nº 576 44-65
hsa-mir-369
SEC ID Nº 577 44-64
hsa-mir-370
SEC ID Nº 578 48-68
hsa-mir-371
SEC ID Nº 579 44-64
hsa-mir-372
SEC ID Nº 580 42-64
hsa-mir-373
SEC ID Nº 581 44-66
hsa-mir-374
SEC ID Nº 582 12-33
hsa-mir-375
SEC ID Nº 677 40-61
hsa-mir-376a
SEC ID Nº 678 44-64
hsa-mir-377
SEC ID Nº 679 45-66
hsa-mir-378
SEC ID Nº 680 5-26 y 44-65
hsa-mir-379
SEC ID Nº 681 6-24
hsa-mir-380
SEC ID Nº 682 5-26 y 40-61
hsa-mir-381
SEC ID Nº 683 49-70
hsa-mir-382
SEC ID Nº 684 11-32
hsa-mir-383
SEC ID Nº 685 7-28
16
E10183543
17-09-2014
(Continuación)
Secuencias miARN Humano
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
hsa-mir-384
SEC ID Nº 686 57-76
hsa-mir-422a
SEC ID Nº 687 11-32
hsa-mir-423
SEC ID Nº 688 53-74
hsa-mir-424
SEC ID Nº 689 11-32
hsa-mir-425
SEC ID Nº 690 55-75
hsa-mir-448
SEC ID Nº 691 71-92
hsa-mir-429
SEC ID Nº 692 51-72
hsa-mir-449
SEC ID Nº 693 16-37
hsa-mir-450-1
SEC ID Nº 694 17-38
hsa-mir-450-2
SEC ID Nº 704 22-43
hsa-mir-451
SEC ID Nº 705 17-39
hsa-mir-452
SEC ID Nº 706 17-38
hsa-mir-453
SEC ID Nº 707 43-64
hsa-mir-455
SEC ID Nº 708 16-37
hsa-mir-483
SEC ID Nº 709 48-70
hsa-mir-484
SEC ID Nº 710 2-23
hsa-mir-485
SEC ID Nº 711 9-30
hsa-mir-486
SEC ID Nº 712 4-25
hsa-mir-487
SEC ID Nº 713 49-70
hsa-mir-488
SEC ID Nº 714 14-34
hsa-mir-489
SEC ID Nº 715 51-73
hsa-mir-490
SEC ID Nº 716 76-97
hsa-mir-491
SEC ID Nº 717 16-38
hsa-mir-492
SEC ID Nº 718 30-52
hsa-mir-493
SEC ID Nº 719 16-37
hsa-mir-494
SEC ID Nº 720 48-71
hsa-mir-495
SEC ID Nº 721 50-72
hsa-mir-496
SEC ID Nº 722 61-77
hsa-mir-497
SEC ID Nº 723 24-44
hsa-mir-498
SEC ID Nº 724 34-56
hsa-mir-499
SEC ID Nº 725 33-55
hsa-mir-500
SEC ID Nº 726 52-73
hsa-mir-501
SEC ID Nº 727 14-35
hsa-mir-502
SEC ID Nº 728 1-21
hsa-mir-503
SEC ID Nº 729 6-28
17
E10183543
17-09-2014
(Continuación)
Secuencias miARN Humano
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
hsa-mir-504
SEC ID Nº 730 13-33
hsa-mir-505
SEC ID Nº 731 52-73
hsa-mir-506
SEC ID Nº 732 71-91
hsa-mir-507
SEC ID Nº 733 56-76
hsa-mir-508
SEC ID Nº 734 61-83
hsa-mir-509
SEC ID Nº 735 55-77
hsa-mir-510
SEC ID Nº 736 10-32
hsa-mir-511-1
SEC ID Nº 737 16-36
hsa-mir-511-2
SEC ID Nº 738 16-36
hsa-mir-512-1
SEC ID Nº 739 14-36
hsa-mir-512-2
SEC ID Nº 740 20-42
hsa-mir-513-1
SEC ID Nº 741 37-58
hsa-mir-513-2
SEC ID Nº 742 36-57
hsa-mir-514-1
SEC ID Nº 743 39-58
hsa-mir-514-2
SEC ID Nº 744 39-58
hsa-mir-514-3
SEC ID Nº 745 39-58
hsa-mir-515-1
SEC ID Nº 746 14-37
hsa-mir-515-2
SEC ID Nº 747 14-37
hsa-mir-516-1
SEC ID Nº 748 61-78
hsa-mir-516-2
SEC ID Nº 749 61-78
hsa-mir-516-3
SEC ID Nº 750 15-37
hsa-mir-516-4
SEC ID Nº 751 15-37
hsa-mir-517a
SEC ID Nº 752 15-36
hsa-mir-517b
SEC ID Nº 753 6-27
hsa-mir-517c
SEC ID Nº 754 20-41
hsa-mir-518a-1
SEC ID Nº 755 14-34
hsa-mir-518a-2
SEC ID Nº 756 15-34
hsa-mir-518b
SEC ID Nº 757 51-72
hsa-mir-518c
SEC ID Nº 758 24-46
hsa-mir-518d
SEC ID Nº 759 16-36
hsa-mir-518e
SEC ID Nº 760 54-75
hsa-mir-518f
SEC ID Nº 761 16-38
hsa-mir-519a-1
SEC ID Nº 762 15-38
hsa-mir-519a-2
SEC ID Nº 763 54-78
hsa-mir-519b
SEC ID Nº 764 13-36
18
E10183543
17-09-2014
(Continuación)
Secuencias miARN Humano
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
hsa-mir-519c
SEC ID Nº 765 16-39
hsa-mir-519d
SEC ID Nº 766 54-76
hsa-mir-519e
SEC ID Nº 767 14-35
hsa-mir-520a
SEC ID Nº 768 15-35
hsa-mir-520b
SEC ID Nº 769 41-61
hsa-mir-520c
SEC ID Nº 770 16-36
hsa-mir-520d
SEC ID Nº 771 15-37
hsa-mir-520e
SEC ID Nº 772 54-74
hsa-mir-520f
SEC ID Nº 773 55-76
hsa-mir-520g
SEC ID Nº 774 55-78
hsa-mir-520h
SEC ID Nº 775 55-76
hsa-mir-521-1
SEC ID Nº 776 54-75
hsa-mir-521-2
SEC ID Nº 777 54-75
hsa-mir-522
SEC ID Nº 778 16-39
hsa-mir-523
SEC ID Nº 779 16-39
hsa-mir-524
SEC ID Nº 780 16-37
hsa-mir-525
SEC ID Nº 781 15-35
hsa-mir-526a-1
SEC ID Nº 782 15-35
hsa-mir-526a-2
SEC ID Nº 783 7-27
hsa-mir-526b
SEC ID Nº 784 14-37
hsa-mir-527
SEC ID Nº 785 14-34
ambi-mir-7100
SEC ID Nº 803
mir-526b*
SEC ID Nº 804
mir-520a*
SEC ID Nº 805
Tabla 2
Secuencias de miARN de ratón
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
mmu-mir-1-1
SEC ID Nº 192 49-69
mmu-mir-1-2
SEC ID Nº 193 47-67
mmu-let-7g
SEC ID Nº 194 7-27
mmu-let-7i
SEC ID Nº 195 6-24
mmu-let-7d
SEC ID Nº 196 16-36 + 70-91
mmu-let-7a-1
SEC ID Nº 197 13-34
mmu-let-7a-2
SEC ID Nº 198 17-38
19
E10183543
17-09-2014
(Continuación)
Secuencias de miARN de ratón
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
mmu-let-7b
SEC ID Nº 199 7-28
mmu-let-7c-1
SEC ID Nº 200 16-37
mmu-let-7c-2
SEC ID Nº 201 14-35
mmu-let-7e
SEC ID Nº 202 15-35
mmu-let-7f-1
SEC ID Nº 203 8-29
mmu-let-7f-2
SEC ID Nº 204 8-29
mmu-mir-7-1
SEC ID Nº 205 24-44
mmu-mir-7-2
SEC ID Nº 206 19-39
mmu-mir-7b
SEC ID Nº 207 30-50
mmu-mir-9-2
SEC ID Nº 208 8-30 y/o 46-66
mmu-mir-9-1
SEC ID Nº 209 16-38 y/o 56-76
mmu-mir-9-3
SEC ID Nº 210 16-38 y/o 56-76
mmu-mir-10b
SEC ID Nº 211 7-28
mmu-mir-10a-1
SEC ID Nº 212 22-44
mmu-mir-10a-2
SEC ID Nº 213 22-44
mmu-mir-15b
SEC ID Nº 214 4-25
mmu-mir-15a
SEC ID Nº 215 15-36
mmu-mir-16-1
SEC ID Nº 216 16-37
mmu-mir-16-2
SEC ID Nº 217 17-38
mmu-mir-17
SEC ID Nº 218 14-37 y/o 51-70
mmu-mir-18
SEC ID Nº 219 17-38
mmu-mir-19b-2
SEC ID Nº 220 54-76
mmu-mir-19a
SEC ID Nº 221 49-71
mmu-mir-19b-1
SEC ID Nº 222 54-76
mmu-mir-20
SEC ID Nº 223 27-49
mmu-mir-21
SEC ID Nº 224 18-39
mmu-mir-22
SEC ID Nº 225 57-78
mmu-mir-23b
SEC ID Nº 226 46-68
mmu-mir-23a
SEC ID Nº 227 46-66
mmu-mir-24-1
SEC ID Nº 228 6-28 y/o 44-65
mmu-mir-24-2
SEC ID Nº 229 61-82
mmu-mir-25
SEC ID Nº 230 52-73
mmu-mir-26a-1
SEC ID Nº 231 16-37
mmu-mir-26b
SEC ID Nº 232 15-36
20
E10183543
17-09-2014
(Continuación)
Secuencias de miARN de ratón
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
mmu-mir-26a-2
SEC ID Nº 233 14-35
mmu-mir-27b
SEC ID Nº 234 49-68
mmu-mir-27a
SEC ID Nº 235 56-76
mmu-mir-28
SEC ID Nº 236 14-35
mmu-mir-29b-1
SEC ID Nº 237 47-68
mmu-mir-29a
SEC ID Nº 238 53-74
mmu-mir-29c
SEC ID Nº 239 54-75
mmu-mir-29b-2
SEC ID Nº 240 52-73
mmu-mir-30a
SEC ID Nº 241 47-68
mmu-mir-30b
SEC ID Nº 242 2-22
mmu-mir-30e
SEC ID Nº 243 2-21
mmu-mir-30c-1
SEC ID Nº 244 17-39
mmu-mir-30c-2
SEC ID Nº 245 14-36
mmu-mir-30d
SEC ID Nº 246 12-33
mmu-mir-31
SEC ID Nº 247 28-49
mmu-mir-32
SEC ID Nº 248 6-26
mmu-mir-33
SEC ID Nº 249 6-24
mmu-mir-34c
SEC ID Nº 250 13-35
mmu-mir-34b
SEC ID Nº 251 13-35
mmu-mir-34a
SEC ID Nº 252 20-42
mmu-mir-92-2
SEC ID Nº 253 55-75
mmu-mir-92-1
SEC ID Nº 254 50-70
mmu-mir-93
SEC ID Nº 255 15-37
mmu-mir-96
SEC ID Nº 256 24-46
mmu-mir-98
SEC ID Nº 257 2-23
mmu-mir-99a
SEC ID Nº 258 6-25
mmu-mir-99b
SEC ID Nº 259 7-28
mmu-mir-100
SEC ID Nº 260 13-34
mmu-mir-101
SEC ID Nº 261 38-57
mmu-mir-101b
SEC ID Nº 262 61-82
mmu-mir-103-1
SEC ID Nº 263 52-74
mmu-mir-103-2
SEC ID Nº 264 52-74
mmu-mir-106a
SEC ID Nº 265 5-26
mmu-mir-106b
SEC ID Nº 266 12-32
mmu-mir-107
SEC ID Nº 267 52-74
21
E10183543
17-09-2014
(Continuación)
Secuencias de miARN de ratón
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
mmu-mir-122a
SEC ID Nº 268 6-28
mmu-mir-124a-3
SEC ID Nº 269 43-64
mmu-mir-124a-1
SEC ID Nº 270 52-73
mmu-mir-124a-2
SEC ID Nº 271 61-82
mmu-mir-125a
SEC ID Nº 272 6-28
mmu-mir-125b-2
SEC ID Nº 273 7-28
mmu-mir-125b-1
SEC ID Nº 274 15-36
mmu-mir-126
SEC ID Nº 275 9-29 y/o 46-66
mmu-mir-127
SEC ID Nº 276 43-64
mmu-mir-128a
SEC ID Nº 277 44-65
mmu-mir-128b
SEC ID Nº 278 48-69
mmu-mir-129-1
SEC ID Nº 279 6-27
mmu-mir-129-2
SEC ID Nº 280 15-36
mmu-mir-130a
SEC ID Nº 281 42-61
mmu-mir-130b
SEC ID Nº 282 51-72
mmu-mir-132
SEC ID Nº 283 42-63
mmu-mir-133a-1
SEC ID Nº 284 44-65
mmu-mir-133a-2
SEC ID Nº 285 60-81
mmu-mir-133b
SEC ID Nº 286 67-87
mmu-mir-134
SEC ID Nº 287 7-27
mmu-mir-135a-1
SEC ID Nº 288 17-39
mmu-mir-135b
SEC ID Nº 289 16-37
mmu-mir-135a-2
SEC ID Nº 290 23-45
mmu-mir-136
SEC ID Nº 291 5-27
mmu-mir-137
SEC ID Nº 292 46-67
mmu-mir-138-2
SEC ID Nº 293 2-18
mmu-mir-138-1
SEC ID Nº 294 23-39
mmu-mir-139
SEC ID Nº 295 7-24
mmu-mir-140
SEC ID Nº 296 7-27
mmu-mir-141
SEC ID Nº 297 49-69
mmu-mir-142
SEC ID Nº 298 4-23 y/o 40-61
mmu-mir-143
SEC ID Nº 299 40-61
mmu-mir-144
SEC ID Nº 300 43-64
mmu-mir-145
SEC ID Nº 301 7-30
mmu-mir-146
SEC ID Nº 302 6-27
22
E10183543
17-09-2014
(Continuación)
Secuencias de miARN de ratón
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
mmu-mir-148a
SEC ID Nº 303 61-82
mmu-mir-149
SEC ID Nº 304 4-25
mmu-mir-150
SEC ID Nº 305 6-27
mmu-mir-151
SEC ID Nº 306 43-63
mmu-mir-152
SEC ID Nº 307 47-67
mmu-mir-153
SEC ID Nº 308 44-63
mmu-mir-154
SEC ID Nº 309 6-27
mmu-mir-155
SEC ID Nº 310 4-25
mmu-mir-181a
SEC ID Nº 311 7-29
mmu-mir-181b-1
SEC ID Nº 312 12-35
mmu-mir-181c
SEC ID Nº 313 17-38
mmu-mir-181b-2
SEC ID Nº 314 16-39
mmu-mir-182
SEC ID Nº 315 7-28
mmu-mir-183
SEC ID Nº 316 6-28
mmu-mir-184
SEC ID Nº 317 45-66
mmu-mir-185
SEC ID Nº 318 7-24
mmu-mir-186
SEC ID Nº 319 7-29
mmu-mir-187
SEC ID Nº 320 40-61
mmu-mir-188
SEC ID Nº 321 6-27
mmu-mir-190
SEC ID Nº 322 6-27
mmu-mir-191
SEC ID Nº 323 7-28
mmu-mir-192
SEC ID Nº 324 14-31
mmu-mir-193
SEC ID Nº 325 41-61
mmu-mir-194-1
SEC ID Nº 326 7-28
mmu-mir-194-2
SEC ID Nº 327 16-37
mmu-mir-195
SEC ID Nº 328 1-21
mmu-mir-196-1
SEC ID Nº 329 24-44
mmu-mir-196-2
SEC ID Nº 330 16-36
mmu-mir-199a-1
SEC ID Nº 331 6-28 y/o 45-66
mmu-mir-199a-2
SEC ID Nº 332 31-53 y/o 69-90
mmu-mir-199b
SEC ID Nº 333 26-48
mmu-mir-200b
SEC ID Nº 334 45-67
mmu-mir-200a
SEC ID Nº 335 54-75
mmu-mir-200c
SEC ID Nº 336 46-67
mmu-mir-201
SEC ID Nº 337 6-26
23
E10183543
17-09-2014
(Continuación)
Secuencias de miARN de ratón
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
mmu-mir-202
SEC ID Nº 33 45-66
mmu-mir-203
SEC ID Nº 339 49-69
mmu-mir-204
SEC ID Nº 340 6-28
mmu-mir-205
SEC ID Nº 341 7-28
mmu-mir-206
SEC ID Nº 342 46-67
mmu-mir-207
SEC ID Nº 343 52-74
mmu-mir-208
SEC ID Nº 344 50-71
mmu-mir-210
SEC ID Nº 345 66-86
mmu-mir-211
SEC ID Nº 346 26-47
mmu-mir-212
SEC ID Nº 347 56-76
mmu-mir-213
SEC ID Nº 348 14-36 y/o 54-75
mmu-mir-214
SEC ID Nº 349 71-91
mmu-mir-215
SEC ID Nº 350 30-50
mmu-mir-216
SEC ID Nº 351 7-27
mmu-mir-217
SEC ID Nº 352 34-57
mmu-mir-218-2
SEC ID Nº 353 25-45
mmu-mir-219-1
SEC ID Nº 354 21-41
mmu-mir-219-2
SEC ID Nº 355 19-39
mmu-mir-221
SEC ID Nº 356 60-81
mmu-mir-222
SEC ID Nº 357 49-71
mmu-mir-223
SEC ID Nº 358 68-88
mmu-mir-224
SEC ID Nº 359 8-30
mu-miR-290
SEC ID Nº 360 15-37
mmu-mir-291
SEC ID Nº 361 14-35 y/o 50-72
mmu-mir-292
SEC ID Nº 362 12-33 y/o 51-73
mmu-mir-293
SEC ID Nº 363 48-69
mmu-mir-294
SEC ID Nº 364 51-72
mmu-mir-295
SEC ID Nº 365 43-65
mmu-mir-296
SEC ID Nº 366 13-33
mmu-mir-297-1
SEC ID Nº 367 15-35
mmu-mir-297-2
SEC ID Nº 368 36-56
mmu-mir-298
SEC ID Nº 369 11-32
mmu-mir-299
SEC ID Nº 370 7-28
mmu-mir-300
SEC ID Nº 371 51-72
mmu-mir-301
SEC ID Nº 372 51-73
24
E10183543
17-09-2014
(Continuación)
Secuencias de miARN de ratón
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
mmu-mir-302
SEC ID Nº 373 44-66
mmu-mir-320
SEC ID Nº 374 48-70
mmu-mir-321
SEC ID Nº 375 10-30
mmu-mir-323
SEC ID Nº 376 50-71
mmu-mir-324
SEC ID Nº 377 18-40 y/o 53-74
mmu-mir-325
SEC ID Nº 378 16-38
mmu-mir-326
SEC ID Nº 379 60-80
mmu-mir-328
SEC ID Nº 380 61-82
mmu-mir-329
SEC ID Nº 381 61-82
mmu-mir-330
SEC ID Nº 382 61-83
mmu-mir-331
SEC ID Nº 383 61-81
mmu-mir-337
SEC ID Nº 384 61-83
mmu-mir-338
SEC ID Nº 385 61-83
mmu-mir-339
SEC ID Nº 386 16-36
mmu-mir-340
SEC ID Nº 387 61-83
mmu-mir-341
SEC ID Nº 388 61-81
mmu-mir-342
SEC ID Nº 389 61-84
mmu-mir-344
SEC ID Nº 390 61-83
mmu-mir-345
SEC ID Nº 391 16-36
mmu-mir-346
SEC ID Nº 392 16-38
mmu-mir-350
SEC ID Nº 393 61-84
mmu-mir-351
SEC ID Nº 583 16-39
mmu-mir-370
SEC ID Nº 584 48-70
mmu-mir-376a
SEC ID Nº 585 44-64
mmu-mir-376b
SEC ID Nº 586 51-72
mmu-mir-380
SEC ID Nº 587 40-61
mmu-mir-409
SEC ID Nº 588 47-69
mmu-mir-410
SEC ID Nº 589 50-71
mmu-mir-411
SEC ID Nº 590 56-78
mmu-mir-412
SEC ID Nº 591 50-72
mmu-mir-425
SEC ID Nº 695 54-74
mmu-mir-429
SEC ID Nº 696 51-72
mmu-mir-448
SEC ID Nº 697 72-93
mmu-mir-449
SEC ID Nº 698 16-37
mmu-mir-450
SEC ID Nº 699 17-38
25
imagen10
E10183543
17-09-2014
(Continuación)
Secuencias de miARN de rata
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
rno-mir-9-2
SEC ID Nº 409 16-38
rno-mir-10a
SEC ID Nº 410 22-44
rno-mir-10b
SEC ID Nº 411 26-47
rno-mir-15b
SEC ID Nº 412 20-41
rno-mir-16
SEC ID Nº 413 17-38
rno-mir-17
SEC ID Nº 414 14-37
rno-mir-18
SEC ID Nº 415 17-38
rno-mir-19b-1
SEC ID Nº 416 54-76
rno-mir-19b-2
SEC ID Nº 417 62-84
rno-mir-19a
SEC ID Nº 418 49-71
rno-mir-20
SEC ID Nº 419 16-38 y/o 52-72
rno-mir-21
SEC ID Nº 420 18-39
rno-mir-22
SEC ID Nº 421 57-78
rno-mir-23a
SEC ID Nº 422 46-66
rno-mir-23b
SEC ID Nº 423 58-80
rno-mir-24-1
SEC ID Nº 424 44-65
rno-mir-24-2
SEC ID Nº 425 61-82
rno-mir-25
SEC ID Nº 426 52-73
mo-mir-26a
SEC ID Nº 427 16-37
rno-mir-26b
SEC ID Nº 428 15-36
rno-mir-27b
SEC ID Nº 429 61-80
rno-mir-27a
SEC ID Nº 430 56-76
rno-mir-28
SEC ID Nº 431 14-35
rno-mir-29b-2
SEC ID Nº 432 52-73
rno-mir-29a
SEC ID Nº 433 53-74
rno-mir-29b-1
SEC ID Nº 434 51-72
rno-mir-29c
SEC ID Nº 435 54-75
rno-mir-30c-1
SEC ID Nº 436 17-39
rno-mir-30e
SEC ID Nº 437 2-21
rno-mir-30b
SEC ID Nº 438 16-36
rno-mir-30d
SEC ID Nº 439 12-33
rno-mir-30a
SEC ID Nº 440 47-68
rno-mir-30c-2
SEC ID Nº 441 14-36
rno-mir-31
SEC ID Nº 442 28-49
rno-mir-32
SEC ID Nº 443 6-26
27
E10183543
17-09-2014
(Continuación)
Secuencias de miARN de rata
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
rno-mir-33
SEC ID Nº 444 6-24
rno-mir-34b
SEC ID Nº 445 13-35
rno-mir-34c
SEC ID Nº 446 13-35
rno-mir-34a
SEC ID Nº 447 20-42
rno-mir-92-1
SEC ID Nº 448 48-68
rno-mir-92-2
SEC ID Nº 449 55-75
rno-mir-93
SEC ID Nº 450 15-37
rno-mir-96
SEC ID Nº 451 24-46
rno-mir-98
SEC ID Nº 452 2-23
rno-mir-99a
SEC ID Nº 453 13-34
rno-mir-99b
SEC ID Nº 454 7-28
rno-mir-100
SEC ID Nº 455 13-34
rno-mir-101b
SEC ID Nº 456 61-82
rno-mir-101
SEC ID Nº 457 47-68
rno-mir-103-2
SEC ID Nº 458 52-74
rno-mir-103-1
SEC ID Nº 459 52-74
rno-mir-106b
SEC ID Nº 460 12-32
rno-mir-107
SEC ID Nº 461 52-74
rno-mir-122a
SEC ID Nº 462 15-37
rno-mir-124a-3
SEC ID Nº 463 52-73
rno-mir-124a-1
SEC ID Nº 464 52-73
rno-mir-124a-2
SEC ID Nº 465 61-82
rno-mir-125a
SEC ID Nº 466 15-37
rno-mir-125b-1
SEC ID Nº 467 15-36
rno-mir-125b-2
SEC ID Nº 468 17-38
rno-mir-126
SEC ID Nº 469 9-29 y/o 46-66
rno-mir-127
SEC ID Nº 470 57-78
mo-mir-128a
SEC ID Nº 471 50-71
mo-mir-128b
SEC ID Nº 472 52-73
rno-mir-129-2
SEC ID Nº 473 19-40 y/o 61-82
rno-mir-129-1
SEC ID Nº 474 6-27
rno-mir-130a
SEC ID Nº 475 55-74
rno-mir-130b
SEC ID Nº 476 51-72
rno-mir-132
SEC ID Nº 477 59-80
rno-mir-133a
SEC ID Nº 478 53-74
28
E10183543
17-09-2014
(Continuación)
Secuencias de miARN de rata
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
rno-mir-134
SEC ID Nº 479 8-28
rno-mir-135b
SEC ID Nº 480 16-37
rno-mir-135a
SEC ID Nº 481 23-45
rno-mir-136
SEC ID Nº 482 15-37
rno-mir-137
SEC ID Nº 483 60-81
rno-mir-138-2
SEC ID Nº 484 9-25
mo-mir-138-1
SEC ID Nº 485 23-39
rno-mir-139
SEC ID Nº 486 7-24
rno-mir-140
SEC ID Nº 487 23-43 y/o 61-84
rno-mir-141
SEC ID Nº 488 59-79
rno-mir-142
SEC ID Nº 489 16-35 y/o 52-74
rno-mir-143
SEC ID Nº 490 60-81
rno-mir-144
SEC ID Nº 491 50-71
rno-mir-145
SEC ID Nº 492 16-39
rno-mir-146
SEC ID Nº 493 17-38
rno-mir-148b
SEC ID Nº 494 61-82
rno-mir-150
SEC ID Nº 495 16-37
rno-mir-151
SEC ID Nº 496 16-37 y/o 50-71
rno-mir-152
SEC ID Nº 497 53-73
rno-mir-153
SEC ID Nº 498 53-72
rno-mir-154
SEC ID Nº 499 15-36
rno-mir-181c
SEC ID Nº 500 24-45
rno-mir-181a
SEC ID Nº 501 39-61
rno-mir-181b-1
SEC ID Nº 502 36-59
rno-mir-181b-2
SEC ID Nº 503 15-38
rno-mir-183
SEC ID Nº 504 27-49
rno-mir-184
SEC ID Nº 505 47-68
rno-mir-185
SEC ID Nº 506 14-31
rno-mir-186
SEC ID Nº 507 15-37
rno-mir-187
SEC ID Nº 508 66-86
rno-mir-190
SEC ID Nº 509 15-36
rno-mir-191
SEC ID Nº 510 15-36
rno-mir-192
SEC ID Nº 511 24-44
rno-mir-193
SEC ID Nº 512 54-74
rno-mir-194-1
SEC ID Nº 513 15-36
29
E10183543
17-09-2014
(Continuación)
Secuencias de miARN de rata
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
rno-mir-194-2
SEC ID Nº 514 15-36
rno-mir-195
SEC ID Nº 515 15-35
rno-mir-196
SEC ID Nº 516 25-45
rno-mir-199a
SEC ID Nº 517 31-53
rno-mir-200c
SEC ID Nº 518 46-67
rno-mir-200a
SEC ID Nº 519 54-75
rno-mir-200b
SEC ID Nº 520 54-77
rno-mir-203
SEC ID Nº 521 52-73
rno-mir-204
SEC ID Nº 522 33-54
rno-mir-205
SEC ID Nº 523 33-54
rno-mir-206
SEC ID Nº 524 51-72
rno-mir-208
SEC ID Nº 525 50-71
rno-mir-210
SEC ID Nº 526 66-86
rno-mir-211
SEC ID Nº 527 26-47
rno-mir-212
SEC ID Nº 528 72-92
rno-mir-213
SEC ID Nº 529 55-76
rno-mir-214
SEC ID Nº 530 71-91
rno-mir-216
SEC ID Nº 531 19-39
rno-mir-217
SEC ID Nº 532 32-55
rno-mir-218-2
SEC ID Nº 533 25-45
rno-mir-218-1
SEC ID Nº 534 25-45
rno-mir-219-1
SEC ID Nº 535 21-41
rno-mir-219-2
SEC ID Nº 536 19-39
rno-mir-221
SEC ID Nº 537 65-87
rno-mir-222
SEC ID Nº 538 62-85
rno-mir-223
SEC ID Nº 539 68-88
rno-mir-290
SEC ID Nº 540 14-36
rno-mir-291
SEC ID Nº 541 14-35 y/o 50-72
rno-mir-292
SEC ID Nº 542 12-33 y/o 51-73
rno-mir-296
SEC ID Nº 543 13-33
rno-mir-297
SEC ID Nº 544 26-48
rno-mir-298
SEC ID Nº 545 11-32
rno-mir-299
SEC ID Nº 546 7-28
rno-mir-300
SEC ID Nº 547 51-72
rno-mir-301
SEC ID Nº 548 61-85
30
E10183543
17-09-2014
(Continuación)
Secuencias de miARN de rata
Nombre de miARN
Precursor Secuencia Procesada Respecto al Precursor
rno-mir-320
SEC ID Nº 549 48-70
rno-mir-321
SEC ID Nº 550 10-30
rno-mir-322
SEC ID Nº 551 61-80
rno-mir-323
SEC ID Nº 552 50-71
rno-mir-324
SEC ID Nº 553 16-38 y/o 51-72
rno-mir-325
SEC ID Nº 554 16-38
rno-mir-326
SEC ID Nº 555 60-80
rno-mir-328
SEC ID Nº 556 48-69
rno-mir-329
SEC ID Nº 557 61-82
rno-mir-330
SEC ID Nº 558 60-82
rno-mir-3 31
SEC ID Nº 559 61-81
rno-mir-333
SEC ID Nº 560 16-35
rno-mir-336
SEC ID Nº 561 16-36
rno-mir-337
SEC ID Nº 562 60-82
rno-mir-338
SEC ID Nº 563 41-63
rno-mir-339
SEC ID Nº 564 16-36
rno-mir-341
SEC ID Nº 565 61-81
rno-mir-342
SEC ID Nº 566 61-84
rno-mir-344
SEC ID Nº 567 61-83
rno-mir-345
SEC ID Nº 568 16-36
rno-mir-346
SEC ID Nº 569 16-38
rno-mir-349
SEC ID Nº 570 61-82
rno-mir-350
SEC ID Nº 571 61-84
rno-mir-351
SEC ID Nº 572 16-39
rno-mir-352
SEC ID Nº 592 61-81
rno-mir-421
SEC ID Nº 593 10-30
rno-mir-429
SEC ID Nº 700 53-74
rno-mir-448
SEC ID Nº 701 72-93
rno-mir-449
SEC ID Nº 702 16-37
rno-mir-450
SEC ID Nº 703 17-38
rno-mir-451
SEC ID Nº 801 17-38
rno-mir-483
SEC ID Nº 802 45-67
Se entiende que un miARN se deriva de secuencias genómicas de un gen. A este respecto, el término “gen” se utiliza por simplicidad para referirse a la secuencia genómica que codifica el precursor de miARN de un determinado
31
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34
imagen35
imagen36
imagen37
imagen38
imagen39
imagen40
imagen41
imagen42
imagen43
imagen44
imagen45
imagen46
imagen47
imagen48
imagen49
imagen50

Claims (1)

ES10183543.7T2004-11-122005-11-14Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARNActiveES2503743T3 (es)

Applications Claiming Priority (6)

Application NumberPriority DateFiling DateTitle
US62717104P2004-11-122004-11-12
US627171P2004-11-12
US64963405P2005-02-032005-02-03
US649634P2005-02-03
US68373605P2005-05-232005-05-23
US683736P2005-05-23

Publications (1)

Publication NumberPublication Date
ES2503743T3true ES2503743T3 (es)2014-10-07

Family

ID=37570916

Family Applications (13)

Application NumberTitlePriority DateFiling Date
ES10183525.4TActiveES2503740T3 (es)2004-11-122005-11-14Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183543.7TActiveES2503743T3 (es)2004-11-122005-11-14Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183589.0TActiveES2534303T3 (es)2004-11-122005-11-14Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183534.6TActiveES2503741T3 (es)2004-11-122005-11-14Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183456.2TActiveES2503738T3 (es)2004-11-122005-11-14Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183596.5TActiveES2534304T3 (es)2004-11-122005-11-14Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183538.7TActiveES2503742T3 (es)2004-11-122005-11-14Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183611.2TActiveES2503765T3 (es)2004-11-122005-11-14Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183462.0TActiveES2534300T3 (es)2004-11-122005-11-14Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183567.6TActiveES2534302T3 (es)2004-11-122005-11-14Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183481.0TActiveES2503739T3 (es)2004-11-122005-11-14Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183490.1TActiveES2534301T3 (es)2004-11-122005-11-14Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183577.5TActiveES2507544T3 (es)2004-11-122005-11-14Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN

Family Applications Before (1)

Application NumberTitlePriority DateFiling Date
ES10183525.4TActiveES2503740T3 (es)2004-11-122005-11-14Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN

Family Applications After (11)

Application NumberTitlePriority DateFiling Date
ES10183589.0TActiveES2534303T3 (es)2004-11-122005-11-14Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183534.6TActiveES2503741T3 (es)2004-11-122005-11-14Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183456.2TActiveES2503738T3 (es)2004-11-122005-11-14Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183596.5TActiveES2534304T3 (es)2004-11-122005-11-14Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183538.7TActiveES2503742T3 (es)2004-11-122005-11-14Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183611.2TActiveES2503765T3 (es)2004-11-122005-11-14Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183462.0TActiveES2534300T3 (es)2004-11-122005-11-14Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183567.6TActiveES2534302T3 (es)2004-11-122005-11-14Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183481.0TActiveES2503739T3 (es)2004-11-122005-11-14Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183490.1TActiveES2534301T3 (es)2004-11-122005-11-14Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
ES10183577.5TActiveES2507544T3 (es)2004-11-122005-11-14Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN

Country Status (11)

CountryLink
US (25)US8173611B2 (es)
EP (21)EP2284265B1 (es)
JP (11)JP2008519606A (es)
AU (1)AU2005333165B2 (es)
CA (7)CA2857901A1 (es)
DK (1)DK2302055T3 (es)
ES (13)ES2503740T3 (es)
HK (1)HK1204656A1 (es)
PL (1)PL2302055T3 (es)
SI (1)SI2302055T1 (es)
WO (1)WO2006137941A2 (es)

Families Citing this family (409)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
WO2003029459A2 (en)2001-09-282003-04-10MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.Micro-rna molecules
EP2290068A3 (en)2004-05-282012-01-04Asuragen, Inc.Methods and compositions involving microRNA
WO2006027776A1 (en)*2004-09-072006-03-16Yissum Research Development Company Of The Hebrew University Of JerusalemAgents, compositions and methods for treating pathologies in which regulating an ache-associated biological pathway is beneficial
US20090186353A1 (en)*2004-10-042009-07-23Rosetta Genomics Ltd.Cancer-related nucleic acids
US7642348B2 (en)*2004-10-042010-01-05Rosetta Genomics LtdProstate cancer-related nucleic acids
US7825229B2 (en)*2005-03-252010-11-02Rosetta Genomics Ltd.Lung cancer-related nucleic acids
EP2284265B1 (en)*2004-11-122015-01-07Asuragen, Inc.Methods and compositions involving miRNA and miRNA inhibitor molecules
EP1877557A2 (en)2005-04-042008-01-16The Board of Regents of The University of Texas SystemMicro-rna's that regulate muscle cells
JP5173793B2 (ja)2005-04-292013-04-03ザ ロックフェラー ユニバーシティマイクロｒｎａ及びそれを阻害する方法
EP1904111A4 (en)*2005-06-032009-08-19Univ Johns Hopkins COMPOSITIONS AND METHODS FOR REDUCING MICRORNA EXPRESSION FOR THE TREATMENT OF NEOPLASIA
CN103820562B (zh)*2005-08-012015-05-13俄亥俄州立大学研究基金会用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物
WO2007033023A2 (en)2005-09-122007-03-22The Ohio State University Research FoundationCompositions and methods for the diagnosis and therapy of bcl2-associated cancers
JP2009511482A (ja)*2005-10-052009-03-19ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイションＷｗｏｘ遺伝子、同じものを含むベクター、および癌の治療における使用
EP1969125B1 (en)*2005-12-122012-06-13The University of North Carolina At Chapel HillMicrornas that regulate muscle cell proliferation and differentiation
AU2016203848B2 (en)*2006-01-052017-12-14The Ohio State University Research FoundationMicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
CA2633674A1 (en)*2006-01-052007-07-19The Ohio State University Research FoundationMicrorna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
WO2007081680A2 (en)2006-01-052007-07-19The Ohio State University Research FoundationMicrorna expression abnormalities in pancreatic endocrine and acinar tumors
EP2487258B1 (en)2006-01-052014-10-01The Ohio State University Research FoundationMicroRNA-based methods for the diagnosis of colon, pancreas and stomach cancer
EP1996731A2 (en)2006-03-202008-12-03The Ohio State University Research FoundationMicrorna fingerprints during human megakaryocytopoiesis
CA2649045C (en)2006-04-032019-06-11Santaris Pharma A/SPharmaceutical composition comprising anti-mirna antisense oligonucleotides
EA201100810A1 (ru)2006-04-032012-06-29Сантарис Фарма А/СФармацевтическая композиция
EP2436783B1 (en)2006-07-132013-09-11The Ohio State University Research FoundationMIR-103-2 for diagnosing poor survival prognosis colon adenocarcinoma.
CA2659364C (en)2006-08-012017-08-22Board Of Regents Of The University Of Texas SystemIdentification of a micro-rna that activates expression of .beta.-myosin heavy chain
AU2007280004A1 (en)†2006-08-042008-02-07Dublin City UniversityA method of producing recombinant biological products
WO2008025073A1 (en)*2006-08-282008-03-06The University Of Western AustraliaMethod of modulation of expression of epidermal growth factor receptor (egfr) involving mirna
WO2008029790A1 (fr)*2006-09-042008-03-13Kyowa Hakko Kirin Co., Ltd.Nouvel acide nucléique
EP2145001A2 (en)*2006-09-192010-01-20Asuragen, Inc.Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
WO2008097277A2 (en)2006-09-192008-08-14The Ohio State University Research FoundationTcl1 expression in chronic lymphocytic leukemia (cll) regulated by mir-29 and mir-181
EP2086590A4 (en)2006-10-242011-04-06Univ Leland Stanford JuniorModulation of t cell signaling threshold and t cell sensitivity to antigens
CA2667617A1 (en)2006-11-012008-05-08The Ohio State University Research FoundationMicrorna expression signature for predicting survival and metastases in hepatocellular carcinoma
US20080131878A1 (en)*2006-12-052008-06-05Asuragen, Inc.Compositions and Methods for the Detection of Small RNA
DK2104737T3 (da)*2006-12-082013-05-27Asuragen IncFunktioner og formål for let-7 mikro-RNAer
CA2671194A1 (en)*2006-12-082008-06-19Asuragen, Inc.Mir-20 regulated genes and pathways as targets for therapeutic intervention
EP2104735A2 (en)*2006-12-082009-09-30Asuragen, INC.Mir-21 regulated genes and pathways as targets for therapeutic intervention
ATE534738T1 (de)*2006-12-082011-12-15Asuragen IncMir-126-regulierte gene und pfade als ziele für therapeutische interventionen
WO2008073915A2 (en)*2006-12-082008-06-19Asuragen, Inc.Micrornas differentially expressed in leukemia and uses thereof
CA2671270A1 (en)*2006-12-292008-07-17Asuragen, Inc.Mir-16 regulated genes and pathways as targets for therapeutic intervention
WO2008088858A2 (en)*2007-01-172008-07-24The Johns Hopkins UniversityCompositions and methods featuring micronas for treating neoplasia
CA2674895A1 (en)2007-01-312008-08-07The Ohio State University Research FoundationMicrorna-based methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia (aml)
CA2699418A1 (en)2007-02-272008-09-04Moshe OrenComposition and methods for modulating cell proliferation and cell death
US9006206B2 (en)2007-02-272015-04-14Rosetta Genomics Ltd.Composition and methods for modulating cell proliferation and cell death
WO2008107901A2 (en)*2007-03-072008-09-12Yissum Research Development Company Of The Hebrew University Of JerusalemAgents, compositions and methods for treating pathologies in which regulating an ache-associated biological pathway is beneficial
US8841436B2 (en)*2007-03-152014-09-23University Hospitals Cleveland Medical CenterScreening, diagnosing, treating and prognosis of pathophysiologic status by RNA regulation
AU2008232316A1 (en)2007-03-262008-10-02Newcastle Innovation LimitedTherapeutic targets and molecules
US20100273172A1 (en)*2007-03-272010-10-28Rosetta Genomics Ltd.Micrornas expression signature for determination of tumors origin
US20090117562A1 (en)2007-04-092009-05-07Valerie Wailin HuMethod and kit for diagnosing Autism using gene expression profiling
CA2685840C (en)*2007-04-302016-12-13The Ohio State University Research FoundationMethods for differentiating pancreatic cancer from normal pancreatic function and/or chronic pancreatitis
EP1990414A1 (en)*2007-05-102008-11-12Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.Means for treating inflammatory diseases, autoimmune diseases and cancer
US20090232893A1 (en)*2007-05-222009-09-17Bader Andreas GmiR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US8415096B2 (en)*2007-05-232013-04-09University Of South FloridaMicro-RNAs modulating immunity and inflammation
CN101711287B (zh)2007-06-082016-04-27由卫生与公众服务部代表的美利坚合众国政府确定肝细胞癌亚型和检测肝癌干细胞的方法
US20090227533A1 (en)*2007-06-082009-09-10Bader Andreas GmiR-34 Regulated Genes and Pathways as Targets for Therapeutic Intervention
EP2167521A4 (en)*2007-06-152011-11-23Univ Ohio State Res Found ONKOGEN ALL-1 FUSION PROTEINS FOR TARGETING DROSHA-MEDIATED microRNA PROCESSING
WO2009006577A2 (en)*2007-07-032009-01-08The Regents Of The University Of MichiganCompositions and methods for inhibiting ezh2
ES2496172T3 (es)*2007-07-312014-09-18The Ohio State University Research FoundationMétodos para invertir la metilación por selección dirigida de DNMT3A y DNMT3B
BRPI0815383A2 (pt)2007-07-312015-09-08Univ Texasfamília de micro-rna que modula fibrose e usos da mesma
CN101808649B (zh)2007-07-312014-05-21得克萨斯系统大学董事会控制肌球蛋白表达和肌纤维身份的微小rna
EP2185700A4 (en)*2007-08-022010-11-24Texas A & M Univ SysAntisense microrna and uses therefor
ES2627059T3 (es)2007-08-032017-07-26The Ohio State University Research FoundationRegiones ultraconservadas que codifican ARNnc
US20120070442A1 (en)*2007-08-092012-03-22The Regents Of The University Of Colorado, A Body CorporateMethods and compositions for treating cancer
CA2733676A1 (en)2007-08-102009-02-19British Columbia Cancer Agency BranchMicrorna compositions and methods for the treatment of myelogenous leukemia
WO2009026487A1 (en)2007-08-222009-02-26The Ohio State University Research FoundationMethods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
CN101376910B (zh)*2007-08-272012-01-11中国科学院上海生命科学研究院微小rna基因在系统性红斑狼疮疾病诊断和治疗中的作用
WO2009033140A1 (en)*2007-09-062009-03-12The Ohio State University Research FoundationMicrorna signatures in human ovarian cancer
WO2009036332A1 (en)2007-09-142009-03-19Asuragen, Inc.Micrornas differentially expressed in cervical cancer and uses thereof
WO2009044895A1 (ja)*2007-10-032009-04-09Kyowa Hakko Kirin Co., Ltd.標的遺伝子の発現を抑制する組成物
WO2009044899A1 (ja)*2007-10-032009-04-09Kyowa Hakko Kirin Co., Ltd.細胞の増殖を制御する核酸
DK2623599T3 (en)2007-10-042019-04-08Roche Innovation Ct Copenhagen As Micromirers
WO2009049129A1 (en)*2007-10-112009-04-16The Ohio State University Research FoundationMethods and compositions for the diagnosis and treatment of esphageal adenocarcinomas
WO2009052386A1 (en)*2007-10-182009-04-23Asuragen, Inc.Micrornas differentially expressed in lung diseases and uses thereof
CN102137927B (zh)2007-10-262014-03-12俄亥俄州立大学研究基金会鉴定脆性组氨酸三联体(Fhit)相互作用的方法及其用途
AU2008318778B2 (en)2007-10-292014-10-02Regulus Therapeutics Inc.Targeting microRNAs for the treatment of liver cancer
JP5968590B2 (ja)*2007-11-052016-08-10ケーシーアイ ライセンシング インコーポレイテッド創面切除のための組織の同定
CN101951924B (zh)*2007-11-092015-06-24得克萨斯系统大学董事会Mir-15家族的微小rna调控心肌细胞存活和心脏修复
ITRM20070595A1 (it)*2007-11-152009-05-16Univ RomaMirna e sirna e loro uso in terapia
EP2215228A4 (en)*2007-11-232012-01-11Panagene Inc MICRORNA ANTISENSE PNAS, COMPOSITIONS AND METHOD FOR THEIR USE AND ASSESSMENT
US20100323357A1 (en)*2007-11-302010-12-23The Ohio State University Research FoundationMicroRNA Expression Profiling and Targeting in Peripheral Blood in Lung Cancer
US8071562B2 (en)*2007-12-012011-12-06Mirna Therapeutics, Inc.MiR-124 regulated genes and pathways as targets for therapeutic intervention
US20090192114A1 (en)*2007-12-212009-07-30Dmitriy OvcharenkomiR-10 Regulated Genes and Pathways as Targets for Therapeutic Intervention
JP5116026B2 (ja)2008-01-232013-01-09富士フイルム株式会社癌の検出方法および癌抑制剤
KR101325186B1 (ko)2008-01-232013-11-07(주)바이오니아이중가닥 ｍｉＲＮＡ를 유효성분으로 포함하는 항암제
WO2009093254A2 (en)*2008-01-272009-07-30Rosetta Genomics Ltd.Methods and compositions for diagnosing complications of pregnancy
US20090263803A1 (en)*2008-02-082009-10-22Sylvie BeaudenonMirnas differentially expressed in lymph nodes from cancer patients
EP3112477A1 (en)*2008-02-282017-01-04The Ohio State University Research FoundationMicrorna-based methods and compositions for the diagnosis, prognosis and treatment of prostate related disorders
US20110034538A1 (en)*2008-02-282011-02-10The Ohio State University Research FoundationMicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Gastric Cancer
EP2254668A4 (en)*2008-02-282012-08-15Univ Ohio State Res Found MICROARN SIGNATURES ASSOCIATED WITH HUMAN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND USES THEREOF
EP2268811A1 (en)2008-03-072011-01-05Santaris Pharma A/SPharmaceutical compositions for treatment of microrna related diseases
JP5653899B2 (ja)*2008-03-172015-01-14ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム神経筋シナプスの維持および再生に関与するマイクロｒｎａの同定
CA2756731A1 (en)2008-03-242009-10-01New York UniversityCompositions and methods for diagnosing and treating melanoma
US20090253780A1 (en)*2008-03-262009-10-08Fumitaka TakeshitaCOMPOSITIONS AND METHODS RELATED TO miR-16 AND THERAPY OF PROSTATE CANCER
WO2009121031A1 (en)*2008-03-272009-10-01Vascular Biosciences, Inc.Methods of novel therapeutic candidate identification through gene expression analysis in vascular-related diseases
CN102046810B (zh)*2008-04-072014-11-19康奈尔研究基金公司血管生成抑制
WO2009126726A1 (en)*2008-04-082009-10-15Asuragen, IncMethods and compositions for diagnosing and modulating human papillomavirus (hpv)
JP2011519951A (ja)*2008-05-072011-07-14アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニーｍｉＲＮＡによる薬物治療の増強
EP2990487A1 (en)2008-05-082016-03-02Asuragen, INC.Compositions and methods related to mirna modulation of neovascularization or angiogenesis
US20110178159A1 (en)*2008-05-082011-07-21Hua GuInhibitory rnas that regulate hematopoietic cells
EP2294218A2 (en)*2008-06-022011-03-16New York UniversityCompositions and methods for diagnosis, prognosis and treatment of mesothelioma
WO2009149318A2 (en)*2008-06-052009-12-10Research Foundation Of State University Of New YorkMirnas as therapeutic targets in cancer
CN102112110A (zh)*2008-06-062011-06-29米尔纳医疗股份有限公司用于RNAi试剂体内递送的新型组合物
US8247388B2 (en)*2008-06-062012-08-21The Board Of Trustees Of The Leland Stanford Junior UniversityRole of miRNA in T cell leukemia
AU2009257410B2 (en)2008-06-112014-03-06Fudan UniversityUse of miR-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy
US8252534B2 (en)*2008-06-122012-08-28City Of HopeMicro RNAs and their methods of use for the treatment and diagnosis of schizophrenia and schizophrenia spectrum disorders
US9540695B2 (en)2008-06-172017-01-10Rosetta Genomics Ltd.Compositions and methods for prognosis of ovarian cancer
US20110077168A1 (en)*2008-06-172011-03-31Nitzan RosenfeldMethods for distinguishing between specific types of lung cancers
JP2011525799A (ja)2008-06-272011-09-29ノバルティス・フォルシュングスシュティフトゥング・ツヴァイクニーダーラッスング・フリードリッヒ・ミーシェー・インスティトゥート・フォー・バイオメディカル・リサーチ抗ウイルス療法の応答の予測
EP2924118A1 (en)2008-07-012015-09-30Monsanto Technology LLCRecombinant DNA constructs and methods for modulating expression of a target gene
JP5322066B2 (ja)2008-07-032013-10-23国立大学法人神戸大学関節リウマチ関連マイクロｒｎａ
WO2010012667A1 (en)2008-08-012010-02-04Santaris Pharma A/SMicro-rna mediated modulation of colony stimulating factors
KR101042052B1 (ko)*2008-08-052011-06-16사회복지법인 삼성생명공익재단항-ｍｉｃｒｏＲＮＡ를 포함하는 고형암 예방 또는 치료용조성물
WO2010017551A2 (en)*2008-08-082010-02-11The General Hospital CorporationMethod for mir-125a in promoting hematopoietic stem cell self renewal and expansion
WO2010019446A1 (en)*2008-08-092010-02-18University Of Iowa Research FoundationNucleic acid aptamers
EP2318016A4 (en)*2008-08-112012-01-18Univ Texas MICRO-RNA AS A PROMOTER OF VEGETABLE INTEGRITY AND USE
CN102149401A (zh)*2008-08-122011-08-10俄亥俄州立大学研究基金会用于多发性骨髓瘤的诊断、预后和治疗的基于微rna的组合物和方法
US20120149586A1 (en)*2008-08-152012-06-14Scottsdale HealthcareMethods of predicting the risk of recurrence of cancer
WO2010022166A2 (en)*2008-08-192010-02-25Maine Institute For Human Genetics And HealthMicro rna (mirna) and neurofibromatosis type 1 : a role in diagnosis and therapy
US9347089B2 (en)2008-09-192016-05-24Children's Medical Center CorporationTherapeutic and diagnostic strategies
EP4219760A3 (en)*2008-11-102023-09-06Battelle Memorial InstituteMethods, compositions, and devices utilizing microrna to determine physiological conditions
US20100179213A1 (en)*2008-11-112010-07-15Mirna Therapeutics, Inc.Methods and Compositions Involving miRNAs In Cancer Stem Cells
EP2633854B1 (en)2008-12-052015-09-16Yeda Research And Development Co. Ltd.miRNA-9 or miRNA-9* for use in treating ALS
CA2745919A1 (en)*2008-12-052010-06-10Whitehead Institute For Biomedical ResearchCompositions and methods relating to mir-31
EP2208785A1 (en)2009-01-152010-07-21Newbiotechnic, S.A.Methods and kits to generate miRNA- and smallRNA-expressing vectors, and its application to develop lentiviral expression libraries
US8492133B2 (en)2009-01-202013-07-23Ramot At Tel Aviv University, Ltd.MIR-21 promoter driven targeted cancer therapy
US9493832B2 (en)2009-02-022016-11-15CepheidMethods of detecting sepsis
KR20110128838A (ko)2009-02-042011-11-30보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템심장 질환 치료에서 ｍｉｒ－208 및 ｍｉｒ－499의 이중 표적화
EP2218458A1 (en)*2009-02-132010-08-18Fondazione TelethonMolecules able to modulate the expression of at least a gene involved in degradative pathways and uses thereof
US20100311815A1 (en)*2009-02-232010-12-09The Regents Of The University Of MichiganMir-101 cancer markers
CN102549166A (zh)*2009-02-262012-07-04俄亥俄州立大学研究基金会从未吸烟者中的MicroRNA及相关材料和方法
US20120029055A1 (en)*2009-03-192012-02-02Agecy for Science, Technology and ResearchModulators of apoptosis and the uses thereof
US20120087992A1 (en)*2009-03-202012-04-12Jingfang JumiRNAS AS THERAPEUTIC TARGETS IN CANCER
EP2414549A4 (en)2009-03-312013-08-28Us Health DIFFERENTIALLY EXPRESSED MICRO-RNAS AS BIOMARKERS FOR THE DIAGNOSIS AND TREATMENT OF SJÖGREN SYNDROME
WO2010120969A1 (en)*2009-04-152010-10-21Board Of Regents, The University Of Texas SystemTargeting of the mir-30 family and let-7 family as a treatment for heart disease
EP2421970B1 (en)2009-04-242016-09-07Roche Innovation Center Copenhagen A/SPharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
DK2425016T3 (en)2009-04-292015-06-29Amc AmsterdamMEANS AND METHODS TO REMEDY THE, PREVENT AND / OR diagnose heart failure or EN risk of cardiac failure
WO2010127186A1 (en)2009-04-302010-11-04Prognosys Biosciences, Inc.Nucleic acid constructs and methods of use
US20120264626A1 (en)*2009-05-082012-10-18The Ohio State University Research FoundationMicroRNA Expression Profiling and Targeting in Chronic Obstructive Pulmonary Disease (COPD) Lung Tissue and Methods of Use Thereof
WO2010129919A1 (en)*2009-05-082010-11-11Research Development FoundationMirna expression in allergic disease
WO2010131162A2 (en)*2009-05-112010-11-18Koninklijke Philips Electronics N.V.Device and method for comparing molecular signatures
AU2010250838B2 (en)2009-05-202016-01-21Eth ZurichTargeting microRNAs for metabolic disorders
MX2011012418A (es)*2009-05-202012-07-20Univ TexasIdentificacion de micro-arns implicados en la remodelacion posterior al infarto de miocardio y en la insuficiencia cardiaca.
DK2435583T3 (da)*2009-05-252014-09-29Universit Degli Studi Di Roma La SapienzamiR-31 VED BEHANDLING AF DUCHENNES MUSKELDYSTROFI
EP2435570A1 (en)*2009-05-252012-04-04Carola PonzettoDifferentiation therapy for sarcomas
JP2012530054A (ja)2009-06-102012-11-29ブレインステム バイオテック リミテッド多能性ストローマ細胞のニューロン分化のための方法、システム及び組成物
US20100322909A1 (en)2009-06-172010-12-23The University Of Pittsburgh - Of The Commonwealth System Of Higher EducationTh1-associated micrornas and their use for tumor immunotherapy
WO2010151755A2 (en)*2009-06-252010-12-29The Brigham And Women's Hospital, Inc.TREATMENT OF INFLAMMATORY DISEASES USING miR-124
WO2011012136A1 (en)*2009-07-282011-02-03Exiqon A/SA method for classifying a human cell sample as cancerous
FR2948687B1 (fr)*2009-07-292015-09-04Centre Nat Rech ScientUtilisation de microarn pour le traitement de pathologies respiratoires chroniques
US8911940B2 (en)2009-07-312014-12-16The Translational Genomics Research InstituteMethods of assessing a risk of cancer progression
WO2011017408A1 (en)*2009-08-052011-02-10The Ohio State University Research FoundationAnti-mir-1 therapy for wound healing
CN102762731B (zh)*2009-08-052018-06-22库尔纳公司通过抑制针对胰岛素基因(ins)的天然反义转录物来治疗胰岛素基因(ins)相关的疾病
EP2283846A1 (en)*2009-08-122011-02-16Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.miRNA compounds for treatment of prostate carcinoma
WO2011034811A1 (en)2009-09-172011-03-24Sigma-Aldrich Co.Short rna mimetics
US20130065949A1 (en)*2009-10-142013-03-14Baylor College Of MedicineMicrorna mirna-31 as a therapeutic approach for the treatment of cancer
US8841273B2 (en)*2009-10-282014-09-23Board Of Regents, The University Of Texas SystemMethods and compositions for anti-EGFR treatment
EP2496714B1 (en)2009-11-042016-08-31DiamiR, LLCMethods of using micro-rna from bodily fluids for diagnosis and monitoring of mild cognitive impairment
CA2781547A1 (en)2009-11-232011-05-26The Ohio State UniversityMaterials and methods useful for affecting tumor cell growth, migration and invasion
EP2504014A4 (en)*2009-11-242013-04-17Univ Western Australia MODULATION OF EPIDERMAL GROWTH FACTOR RECEPTOR LIGANDS
EP2327783A1 (en)*2009-11-272011-06-01Universitätsklinikum FreiburgPharmaceutical composition comprising miRNA-100 and its use in the modulation of blood vessel growth
US8354520B2 (en)*2009-12-102013-01-15Kaohsiung Medical UniversityComposition and method for treating atherosclerosis, method for determining if a subject has atherosclerosis and method of screening an anti-atherosclerotic drug
US20120315640A1 (en)2009-12-212012-12-13Hidetoshi TaharaSenescence marker, method for evaluating senescence inhibitor, and cancer inhibitor
WO2011084815A1 (en)*2009-12-212011-07-14Board Of Trustees Of Southern Illinois UniversityInhibition of ubc9-mediated cancer cell invasion and metastasis
JP5804459B2 (ja)*2009-12-212015-11-04国立大学法人広島大学癌疾患用細胞老化促進剤
WO2011079299A1 (en)*2009-12-232011-06-30The George Washington UniversityCompositions and methods for identifying autism spectrum disorders
EP2341145A1 (en)*2009-12-302011-07-06febit holding GmbHmiRNA fingerprint in the diagnosis of diseases
US8846631B2 (en)2010-01-142014-09-30Regulus Therapeutics Inc.MicroRNA compositions and methods
US20130005759A1 (en)*2010-01-212013-01-03North Carolina State UniversitySmall molecule modifiers of microrna mir-122
JP2011188849A (ja)*2010-02-182011-09-29Okayama Univ抗腫瘍効果を有するｍｉＲ−７発現プラスミド
US8841269B2 (en)*2010-02-232014-09-23Creighton UniversityPolynucleotides for use in treating and diagnosing cancers
ES2631458T3 (es)*2010-03-042017-08-31Interna Technologies B.V.Molécula de ARNmi definida por su fuente y sus usos terapéuticos en el cáncer asociado a la EMT
WO2011111715A1 (ja)*2010-03-092011-09-15協和発酵キリン株式会社細胞周期を制御する核酸
US20190300945A1 (en)2010-04-052019-10-03Prognosys Biosciences, Inc.Spatially Encoded Biological Assays
HUE026666T2 (en)2010-04-052016-07-28Prognosys Biosciences Inc Spatially encoded biological assays
US10787701B2 (en)2010-04-052020-09-29Prognosys Biosciences, Inc.Spatially encoded biological assays
SI2561078T1 (sl)2010-04-232019-01-31Cold Spring Harbor LaboratoryNove strukturno oblikovane shRNA
WO2011150420A1 (en)*2010-05-282011-12-01Baylor College Of MedicineModified gold nanoparticles for therapy
EP2576785A4 (en)2010-06-042014-12-24Univ Texas REGULATION OF METABOLISM BY MIR-378
EP2711422B1 (en)*2010-06-092014-10-01Chanel Parfums BeautéInhibitors of micro-RNAs for use for preventing and/or attenuating skin ageing and/or for hydrating skin
NZ719520A (en)*2010-07-062017-07-28Int Tech BvMirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
US9476041B2 (en)*2010-07-122016-10-25National University Corporation Tottori UniversityMethod for producing novel hipsc by means of siRNA introduction
US8580513B2 (en)*2010-07-202013-11-12Trustees Of Dartmouth CollegeMethods for determining response to neoadjuvant therapy and survival using MicroRNA-10b
WO2012012716A2 (en)2010-07-232012-01-26Regulus Therapeutics, Inc.Targeting micrornas for the treatment of fibrosis
EP2606123A4 (en)2010-08-162014-01-15Brainstem Biotec Ltd METHOD OF GENERATING OLIGOD DROCYTES AND CELL POPULATIONS THEREWITH
US10385314B2 (en)2010-08-162019-08-20Exostem Biotec Ltd.Methods of generating oligodendrocytes and cell populations comprising same
AU2011292809B2 (en)*2010-08-172017-04-13Hopitaux Universitaires De GeneveBARD1 isoforms in lung and colorectal cancer and use thereof
US8642342B2 (en)2010-08-192014-02-04Regents Of The University Of MichiganMethods for regulating neural differentiation
EP2426217A1 (en)*2010-09-032012-03-07Centre National de la Recherche Scientifique (CNRS)Analytical methods for cell free nucleic acids and applications
US9006195B2 (en)*2010-09-132015-04-14California Institute Of TechnologyRegulation of hematopoietic stem cell functions through microRNAs
CA2812650C (en)*2010-09-272019-11-05Sabanci UniversitesiUse of mirnas for the diagnosis, prophylaxis, treatment and follow-up of diseases involving macroautophagy abnormalities
US8933051B2 (en)2010-09-302015-01-13University Of ZurichTreatment of B-cell lymphoma with microRNA
EP2638912A4 (en)*2010-11-122015-01-21Nat Univ Corp Ehime Univ COMPOSITIONS WITH AN ANTISENSE OLIGONUCLEOTIDE AGAINST MICRO RNA
ES2606146T3 (es)*2010-11-122017-03-22The Ohio State University Research FoundationMétodos relacionados con microARN-21 y reparación de desapareamiento en cáncer colorrectal
AU2011329066B2 (en)2010-11-152017-03-09The Ohio State University Research FoundationControlled release mucoadhesive systems
EP2640851A2 (en)2010-11-172013-09-25Asuragen, Inc.Mirnas as biomarkers for distinguishing benign from malignant thyroid neoplasms
US12318420B2 (en)2010-12-012025-06-03Gowey Research Group, PllcHerbal formulations of carnivorous plants and methods for treating inflammation
US10744151B1 (en)*2010-12-012020-08-18Gowey Research Group PLLCMicro-RNA profiling, compositions, and methods of treating diseases
US11344505B1 (en)2010-12-012022-05-31Gowey Research Group, PllcHerbal formulations of carnivorous plants and methods for treating inflammation
US11414663B2 (en)2010-12-012022-08-16Gowey Research Group, PllcMicro-RNA profiling, compositions, and methods of treating diseases
US10758578B2 (en)2010-12-012020-09-01Gowey Research Group PLLCHerbal formulations of carnivorous plants and methods for treating inflammation
EP3214185A1 (en)*2010-12-012017-09-06INSERM (Institut National de la Santé et de la Recherche Médicale)Method for predicting the outcome of colon cancer by analysing mirna expression
US20140045924A1 (en)*2010-12-152014-02-13Medimmune, LlcMelanoma treatments
BR112013012319A2 (pt)2010-12-152019-09-24Miragen Therapeuticsinibidores de micro rna compreendendo nucleotídeos bloqueados
SG191174A1 (en)*2010-12-202013-07-31Agency Science Tech & ResTargeting glioma stem cells by sequence-specific functional inhibition of pro-survival oncomir-138
EP2474617A1 (en)2011-01-112012-07-11InteRNA Technologies BVMir for treating neo-angiogenesis
MX342927B (es)2011-02-032016-10-19Mirna Therapeutics IncMimeticos sinteticos de mir-34.
CN103459598B (zh)2011-02-032016-08-10米尔纳医疗股份有限公司Mir-124的合成模拟物
SMT201900474T1 (it)*2011-02-072019-09-09Gabriella SozziMicrorna biomarcatori per identificare il rischio di e/o per diagnosticare tumore ai polmoni
US8664192B2 (en)2011-03-072014-03-04The Ohio State UniversityMutator activity induced by microRNA-155 (miR-155) links inflammation and cancer
EP2691522B1 (en)*2011-03-302020-11-25Transine Therapeutics LimitedFunctional nucleic acid molecule and use thereof
EP2691548B1 (en)*2011-03-312017-11-22University of HoustonMicrorna 130a,b as a tumor suppressor and sensitizing agent for chemotherapy
GB201106254D0 (en)2011-04-132011-05-25Frisen JonasMethod and product
WO2012140234A1 (en)2011-04-132012-10-18Vib VzwModulation of mirna in diseases with aberrant angiogenesis
CN105861712B (zh)2011-04-182021-05-14迪阿米尔有限责任公司使用来自体液的miRNA来早期检测和监控轻度认知障碍(MCI)和阿尔茨海默病(AD)的方法
WO2012145743A1 (en)*2011-04-222012-10-26University Of HoustonMicrorna-140-5p as a tumor suppressor and sensitizing agent for chemotherapy
ES2868950T3 (es)2011-04-252021-10-22Sanofi SaCompuestos de microARN y métodos para modular la actividad de miR-21
EE201100037A (et)*2011-05-162012-12-17Tartu ÜlikoolMikroRNAde kasutamine biomarkeritena ja sihtm„rkidena raku proliferatiivsete omaduste m?jutamiseks ja meetod ning komplekt nende ekspressioonitaseme tuvastamiseks
MX383670B (es)2011-06-272025-03-14Galderma Res & DevNuevos marcadores de la diferenciación de th17 para el acné y usos de los mismos.
CA2840405A1 (en)*2011-06-272013-01-03Galderma Research & DevelopmentNew th17 differentiation markers for acne and uses thereof
US8747860B2 (en)2011-07-062014-06-10Institute For Systems BiologyMethods and compositions to modulate antiviral and immune activity responses
EP2740266A1 (en)2011-08-012014-06-11Thomson LicensingTelepresence communications system and method
EP2739736B1 (en)2011-08-042017-04-19Yeda Research and Development Co. Ltd.Mir-135 and compositions comprising same for the treatment of serotonin associated medical conditions
US8987224B2 (en)*2011-08-052015-03-24Baylor College Of MedicineMicroRNA-198 as a tumor suppressor in pancreatic cancer
CA2840030A1 (en)2011-08-122013-02-21Westfaelische Wilhelms-Universitaet MuensterNovel compounds for the treatment of inflammatory bowel disease
WO2013032962A2 (en)*2011-08-282013-03-07The Board Of Trustees Of The Leland Stanford Junior UniversityMicro rnas to treat stroke, ischemic brain injury, traumatic brain injury, and neurodegenerative disease
US9434944B2 (en)2011-08-312016-09-06University Of ZurichModulators of miR-323-3p for the prevention or treatment of rheumatoid arthritis
US9018188B2 (en)2011-09-132015-04-28Ottawa Hospital Research InstituteMicroRNA inhibitors
US9644241B2 (en)2011-09-132017-05-09Interpace Diagnostics, LlcMethods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
EP2763703B1 (en)2011-10-062018-02-14Miragen Therapeutics, Inc.Control of whole body energy homeostasis by microrna regulation
JP2014530612A (ja)2011-10-142014-11-20ジ・オハイオ・ステート・ユニバーシティ卵巣がんに関する方法および材料
EP2584040A1 (en)2011-10-172013-04-24Pharmahungary 2000 Kft.Compounds for treatment of ischemic injury
WO2013065791A1 (ja)*2011-11-022013-05-10公立大学法人大阪市立大学遺伝子発現抑制用二本鎖核酸分子
EP3106168A3 (en)*2011-11-302017-02-22Cedars-Sinai Medical CenterTargeting micrornas mir-409-5p, mir-379 and mir-154* to treat prostate cancer bone metastasis and drug resistant lung cancer
CN105722993A (zh)*2011-12-012016-06-29俄亥俄州国家创新基金会与结肠直肠癌的nsaid化学预防相关的材料和方法
CA2858382A1 (en)*2011-12-102013-06-13Ohio State Innovation FoundationMirnas useful to reduce lung cancer tumorigenesis and chemotherapy resistance and related compositons and methods
WO2013090556A1 (en)*2011-12-132013-06-20The Ohio State UniversityMethods and compositions related to mir-21 and mir-29a, exosome inhibition, and cancer metastasis
ITRM20110685A1 (it)2011-12-232013-06-24Internat Ct For Genetic En Gineering AndMicrorna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci
WO2013110053A1 (en)2012-01-202013-07-25The Ohio State UniversityBreast cancer biomarker signatures for invasiveness and prognosis
US9803175B2 (en)2012-02-222017-10-31Exostem Biotec Ltd.Generation of neural stem cells and motor neurons
EP2844744A2 (en)2012-02-222015-03-11Brainstem Biotec Ltd.MicroRNAS FOR THE GENERATION OF ASTROCYTES
CN104160708B (zh)2012-03-092018-12-11汤姆逊许可公司同步内容的分布式控制
UA117098C2 (uk)2012-04-252018-06-25Рег'Юлес Терап'Ютікс Інк.Сполука, що містить модифікований олігонуклеотид
US9598694B2 (en)2012-05-022017-03-21The Board Of Regents Of The University Of Texas SystemMicro-RNAs involved in macular degeneration
US9334498B2 (en)2012-05-102016-05-10Uab Research FoundationMethods and compositions for modulating MIR-204 activity
WO2013180038A1 (ja)2012-05-262013-12-05株式会社ボナックデリバリー機能を有する遺伝子発現制御用の一本鎖核酸分子
US9388408B2 (en)2012-06-212016-07-12MiRagen Therapeutics, Inc.Oligonucleotide-based inhibitors comprising locked nucleic acid motif
US9163235B2 (en)2012-06-212015-10-20MiRagen Therapeutics, Inc.Inhibitors of the miR-15 family of micro-RNAs
CN104603272B (zh)*2012-07-062017-11-07宝生物工程株式会社能够产生腺伴随病毒载体的细胞
US9545420B2 (en)2012-07-272017-01-17Agency For Science, Technology And ResearchMethod of promoting wound healing
CN104684558A (zh)2012-07-312015-06-03耶达研究及发展有限公司诊断和治疗运动神经元疾病的方法
ES2534210T3 (es)*2012-08-292015-04-20Chanel Parfums BeautéInhibidores de micro-ARN para uso para prevenir y/o atenuar el envejecimiento cutáneo
EP2702998A1 (en)2012-08-312014-03-05IMBA-Institut für Molekulare Biotechnologie GmbHTherapeutic and diagnostic miRNA regulator in kidney disease
WO2014043159A1 (en)*2012-09-112014-03-20New York UniversitySera based mirnas as non-invasive biomarkers in melanoma
UA116639C2 (uk)2012-10-092018-04-25Рег'Юлес Терап'Ютікс Інк.Способи лікування синдрому альпорта
WO2014060483A1 (en)2012-10-172014-04-24Spatial Transcriptomics AbMethods and product for optimising localised or spatial detection of gene expression in a tissue sample
WO2014071205A1 (en)*2012-11-022014-05-08Dana-Farber Cancer Institute, Inc.Compositions and methods for diagnosis, prognosis and treatment of hematological malignancies
US9340787B2 (en)*2012-11-152016-05-17Yale UniversityCompositions and methods of using micro RNAs
US20140243387A1 (en)*2012-12-182014-08-28Icahn School Of Medicine At Mount SinaiMethods for improving cardiac contractility
DK2963125T3 (da)*2013-02-152020-10-12Univ Nat Corp Tokyo Medical & DentalTerapeutisk middel til behandling af en cancer, hvor NRF2 er stabiliseret
WO2014164753A1 (en)*2013-03-112014-10-09Emory UniversityMethods and compositions for managing vascular conditions
US9006200B2 (en)*2013-03-132015-04-14Asbestos Diseases Research FoundationMicroRNA-based approach to treating malignant pleural mesothelioma
CN105188715B (zh)2013-03-152018-12-25米拉根医疗股份有限公司Mir-145的锁定核酸抑制剂及其用途
WO2014152243A1 (en)*2013-03-152014-09-25Albert Einstein College Of Medicine Of Yeshiva UniversityPanel of microrna biomarkers in healthy aging
CA2903882A1 (en)2013-03-152014-09-18Mirna Therapeutics, Inc.Combination cancer treatments utilizing micrornas and egfr-tki inhibitors
WO2014140856A2 (en)2013-03-152014-09-18Graham LordMir-142 and antagonists thereof for treating disease
US9756288B2 (en)2013-04-102017-09-05Thomson LicensingTiering and manipulation of peer's heads in a telepresence system
JP2016169158A (ja)*2013-06-142016-09-23北海道公立大学法人 札幌医科大学大腸癌を治療および／または診断するための組成物ならびにその利用
GB201310755D0 (en)*2013-06-172013-07-31Ucl Business PlcTherapy
WO2014204459A1 (en)2013-06-202014-12-24Thomson LicensingSystem and method to assist synchronization of distributed play out of control
EP3013975A1 (en)2013-06-242016-05-04Mirna Therapeutics, Inc.Biomarkers of mir-34 activity
CN105849275B (zh)2013-06-252020-03-17普罗格诺西斯生物科学公司检测样品中生物靶标的空间分布的方法和系统
US9862943B1 (en)*2013-06-272018-01-09California Institute Of TechnologyLong noncoding RNAs and cell reprogramming and differentiation
WO2015020122A1 (ja)*2013-08-082015-02-12国立大学法人 大阪大学尿路上皮癌の診断または治療剤
KR101566586B1 (ko)*2013-08-212015-11-16서울대학교산학협력단miRNA를 표적으로 하는 뇌전증 또는 발작 관련 질환의 예방 또는 치료용 약학 조성물 및 방법
EP3049522A2 (en)*2013-09-262016-08-03Friedrich Miescher Institute for Biomedical ResearchTools and methods using mirna 182, 96 and/or 183 for treating pathologies
US20150089870A1 (en)*2013-10-012015-04-02Wayne State UniversityPopulation control of invasive plant species and restoration of native plant communities
KR101598070B1 (ko)*2013-10-172016-02-26한국과학기술연구원마약 중독 예방 및 치료용 약제학적 조성물
USRE50566E1 (en)2013-10-282025-09-02Icahn School Of Medicine At Mount SinaiCompositions and methods for modulating neuronal excitability and motor behavior
KR101559131B1 (ko)*2013-11-182015-10-07한국원자력의학원ｍｉＲＮＡ를 포함하는 방사선 민감성 증진용 조성물
CA2931082C (en)2013-11-182024-01-23Diamir, LlcMethods of using mirnas from bodily fluids for detection and monitoring of parkinson's disease (pd)
EP3178943B1 (en)2013-12-172018-10-03CsirA method for identification of anti-hiv human mirna mimics and mirna inhibitors and anti-hiv pharmaceutical compounds
WO2015099122A1 (ja)*2013-12-262015-07-02学校法人東京医科大学遺伝子発現制御のための人工ミミックｍｉＲＮＡおよびその用途
CN106068324B (zh)*2013-12-272020-12-29株式会社博纳克控制基因表达的人工匹配型miRNA及其用途
JP6492014B2 (ja)*2013-12-272019-03-27株式会社ボナック遺伝子発現制御のための人工マッチ型ｍｉＲＮＡおよびその用途
US10125365B2 (en)2014-02-052018-11-13Yeda Research And Development Co. Ltd.Micro-RNAs and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
JPWO2015133637A1 (ja)*2014-03-072017-04-06国立大学法人京都大学マイクロｒｎａ封入ナノ粒子及びその医薬用途
US20160136181A1 (en)2014-04-012016-05-19Mirna Therapeutics, IncMicrorna dosing regimens
ES2877689T3 (es)*2014-05-022021-11-17Univ Heidelberg Ruprecht KarlsmiARN circulantes como marcador de detección temprana y marcador pronóstico
AU2015279542B2 (en)*2014-06-262021-07-29Icahn School Of Medicine At Mount SinaiMethod for diagnosing subclinical and clinical acute rejection by analysis of predictive gene sets
WO2016010023A1 (ja)*2014-07-152016-01-21株式会社ミツバブラシレスワイパモータ
LU92499B1 (en)2014-07-162016-01-18Univ Muenster WilhelmsMirna 320a as biomarker for inflammatory bowel disease
ES2558262B2 (es)2014-08-012016-07-14Universidad Católica De Valencia "San Vicente Mártir"Método de diagnóstico de fibromialgia basado en microRNAs
AU2015301057A1 (en)2014-08-072017-01-19Regulus Therapeutics Inc.Targeting micrornas for metabolic disorders
US20170298352A1 (en)*2014-09-302017-10-19Research Institute at Nationwide Children's Hospit alCompositions and methods for treating hepatic fibrosis
KR20170098914A (ko)*2014-12-272017-08-30가부시키가이샤 보낙유전자 발현 제어를 위한 천연형 miRNA 및 그의 용도
SG10201906716QA (en)2015-01-202019-08-27Miragen Therapeutics IncMir-92 inhibitors and uses thereof
GB201504772D0 (en)*2015-03-202015-05-06Univ AstonPreeclampsia
EP4218771A1 (en)2015-03-272023-08-02Yeda Research and Development Co. LtdMethods of treating motor neuron diseases
EP3276003B1 (en)2015-03-272022-07-20Bonac CorporationSingle-chain nucleic acid molecule having delivery function and gene expression control ability
CA2982146A1 (en)2015-04-102016-10-13Spatial Transcriptomics AbSpatially distinguished, multiplex nucleic acid analysis of biological specimens
EP3284822A1 (en)*2015-04-172018-02-21The University of TokyoTherapeutic agent for eye disease
US20180142297A1 (en)*2015-05-142018-05-24Arizona Board Of Regents On Behalf Of The University Of ArizonaSystems and methods for characterizing granulomatous diseases
WO2016190899A1 (en)*2015-05-232016-12-01Beem Alan M HPri-mirna libraries and methods for making and using pri-mirna libraries
IL316159A (en)2015-06-152024-12-01Mpeg La LlcDefined Oligonucleotide Multimers and Methods for Manufacture Thereof
WO2017020009A1 (en)*2015-07-302017-02-02Regents Of The University Of MinnesotaRegulation of mesodermal specification
WO2017027839A1 (en)2015-08-132017-02-16Somagenics, Inc.Methods and compositions of short small hairpin rnas and micrornas for wound healing
WO2017032776A1 (en)*2015-08-212017-03-02Universitätsklinikum JenaHuman micrornas for treatment of malignant tumours
EP3357498A4 (en)*2015-09-282019-05-15National University Corporation Chiba University PROCESS FOR SUPPRESSING TUMORS BY INHIBITING THE MIR-200 FAMILY
EP3356553A1 (en)2015-09-292018-08-08The Research Institute at Nationwide Children's HospitalMethods for detecting hepatic fibrosis and responsiveness to therapy
JP6666002B2 (ja)*2015-10-072020-03-13国立大学法人京都大学Ｔｄｐ−４３プロテノパシーの予防又は治療用組成物
WO2017098052A1 (en)*2015-12-102017-06-15Universität Für Bodenkultur WienCompositions and methods for the diagnosis and treatment of bone fractures and disorders
EP3181698A1 (en)2015-12-162017-06-21European Molecular Biology Laboratory (EMBL)Microrna mir-142 as stem cell marker
CA3001536A1 (en)*2015-12-282017-07-06RikenCompositions for use in recovering or ameliorating deterioration of physiological functions due to aging
US10975436B2 (en)2016-01-052021-04-13Diamir, LlcMethods of using miRNA from bodily fluids for diagnosis and monitoring of neurodevelopmental disorders
CN105543225A (zh)*2016-01-072016-05-04华东师范大学miR143及其诱导物LTA在制备抑制痤疮炎症药物中的应用
US10771508B2 (en)2016-01-192020-09-08Nadejda SarmovaSystems and methods for establishing a virtual shared experience for media playback
US11364258B2 (en)2016-03-042022-06-21Rhode Island HospitalMethods for treating chondrosarcoma using microrna(miR)
ES2993025T3 (en)2016-03-212024-12-20Diamir LlcMethods of using mirnas from bodily fluids for detection and differentiation of neurodegenerative diseases
EP3444345B1 (en)*2016-04-142024-07-10e-NA Biotec Inc.microRNA-143 DERIVATIVE
US11389479B2 (en)2016-05-022022-07-19University Of MassachusettsT cell differentiation and function regulation by decreasing let7 expression
CN115814097A (zh)*2016-06-032023-03-21霍夫耳科研究所用于内耳感觉毛细胞再生/替换的联合疗法
US10874688B2 (en)2016-10-312020-12-29Gifu UniversityDouble-stranded nucleic acid molecule and use thereof
US11584932B2 (en)2016-11-012023-02-21The Research Foundation For The State University Of New York5-halouracil-modified microRNAs and their use in the treatment of cancer
CN107058470B (zh)*2016-11-032020-09-01中国人民解放军陆军军医大学一种通过联合miR-136和miR-4791预测急性高山病发病风险的诊断试剂盒
AU2017368050A1 (en)2016-11-292019-06-20Puretech Lyt, Inc.Exosomes for delivery of therapeutic agents
WO2018191895A1 (zh)2017-04-192018-10-25深圳市汇顶科技股份有限公司光强检测方法、装置及智能终端
JP7083818B2 (ja)*2017-04-282022-06-13一丸ファルコス株式会社プラセンタ抽出物
WO2018204829A1 (en)*2017-05-042018-11-08University Of Maryland, BaltimoreMethods for preventing neural tube defects in diabetic pregnancy
CN110636853B (zh)*2017-05-192024-10-18佐治亚州立大学研究基金会公司重组溶瘤病毒
US20210139895A1 (en)*2017-06-162021-05-13Prostemics Co., Ltd.Pharmaceutical composition for preventing or treating cancer
US10781487B2 (en)2017-07-242020-09-22Diamir, LlcmiRNA-based methods for detecting and monitoring aging
WO2019116234A1 (en)2017-12-122019-06-20Nestec S.A.Methods for determining microbiome ribosomal rna composition changes
RU2020132725A (ru)*2018-03-142022-04-15Бет Израэль Диконесс Медикал СентрМикро-рнк и ожирение
US10716866B2 (en)2018-03-292020-07-21Generoath Co., LtdPharmaceutical composition comprising AIMP2-DX2 for preventing or treating neuronal diseases and use thereof
WO2019195765A1 (en)*2018-04-062019-10-10University Of MassachusettsMlk-regulated micrornas in angiogenesis and tumor development
US11519033B2 (en)2018-08-282022-12-0610X Genomics, Inc.Method for transposase-mediated spatial tagging and analyzing genomic DNA in a biological sample
KR102115960B1 (ko)*2018-11-282020-05-27송미연인간 중간엽 줄기세포를 갑상선 호르몬 분비세포로 분화 방법
WO2020123319A2 (en)2018-12-102020-06-1810X Genomics, Inc.Methods of using master / copy arrays for spatial detection
US11649485B2 (en)2019-01-062023-05-1610X Genomics, Inc.Generating capture probes for spatial analysis
US11926867B2 (en)2019-01-062024-03-1210X Genomics, Inc.Generating capture probes for spatial analysis
CN113924127A (zh)*2019-03-112022-01-11奥克斯纳健康系统公司在患有自发性脑内出血的患者中作为癫痫发作的生物标志物的微rna调节网络
KR102248420B1 (ko)*2019-03-152021-05-06주식회사 제너로스miR-142-3p의 표적 서열을 포함하는 재조합 벡터
US20220251552A1 (en)*2019-03-252022-08-11The Trustees Of The University Of PennsylvaniaRegenerative Therapy Based on miRNA-302 Mimics for Enhancing Host Recovery from Pneumonia Caused by Streptococcus pneumoniae
EP3956474A1 (en)*2019-04-182022-02-23INSERM (Institut National de la Santé et de la Recherche Médicale)Methods for the treatment and prognosis of cancer
BR112021021310A2 (pt)*2019-04-242021-12-14Nevada Res & Innovation CorporationMétodos e composições de miméticos de mir-10 e seus alvos
EP3976820A1 (en)2019-05-302022-04-0610X Genomics, Inc.Methods of detecting spatial heterogeneity of a biological sample
US11198908B2 (en)2019-06-172021-12-14Biorchestra Co., Ltd.Method for diagnosis of Alzheimer's disease using microRNA
US10844380B1 (en)2019-06-172020-11-24Biorchestra Co., Ltd.Uses for prevention or treatment of brain diseases using microrna
CN110551809A (zh)*2019-08-212019-12-10昆明医科大学第一附属医院miR-124在脊髓损伤修复中的用途
WO2021091611A1 (en)2019-11-082021-05-1410X Genomics, Inc.Spatially-tagged analyte capture agents for analyte multiplexing
WO2021092433A2 (en)2019-11-082021-05-1410X Genomics, Inc.Enhancing specificity of analyte binding
WO2021133842A1 (en)2019-12-232021-07-0110X Genomics, Inc.Compositions and methods for using fixed biological samples in partition-based assays
AU2020412766C1 (en)2019-12-232025-01-0210X Genomics, Inc.Methods for spatial analysis using RNA-templated ligation
US12037585B2 (en)2019-12-232024-07-16University Of MassachusettsOligonucleotides for tissue specific gene expression modulation
US12365942B2 (en)2020-01-132025-07-2210X Genomics, Inc.Methods of decreasing background on a spatial array
US12405264B2 (en)2020-01-172025-09-0210X Genomics, Inc.Electrophoretic system and method for analyte capture
US11732299B2 (en)2020-01-212023-08-2210X Genomics, Inc.Spatial assays with perturbed cells
US11702693B2 (en)2020-01-212023-07-1810X Genomics, Inc.Methods for printing cells and generating arrays of barcoded cells
US20210230681A1 (en)2020-01-242021-07-2910X Genomics, Inc.Methods for spatial analysis using proximity ligation
US11821035B1 (en)2020-01-292023-11-2110X Genomics, Inc.Compositions and methods of making gene expression libraries
US12076701B2 (en)2020-01-312024-09-0310X Genomics, Inc.Capturing oligonucleotides in spatial transcriptomics
US11898205B2 (en)2020-02-032024-02-1310X Genomics, Inc.Increasing capture efficiency of spatial assays
US12110541B2 (en)2020-02-032024-10-0810X Genomics, Inc.Methods for preparing high-resolution spatial arrays
US11732300B2 (en)2020-02-052023-08-2210X Genomics, Inc.Increasing efficiency of spatial analysis in a biological sample
WO2021158925A1 (en)2020-02-072021-08-1210X Genomics, Inc.Quantitative and automated permeabilization performance evaluation for spatial transcriptomics
US11835462B2 (en)2020-02-112023-12-0510X Genomics, Inc.Methods and compositions for partitioning a biological sample
US12281357B1 (en)2020-02-142025-04-2210X Genomics, Inc.In situ spatial barcoding
US12399123B1 (en)2020-02-142025-08-2610X Genomics, Inc.Spatial targeting of analytes
US11891654B2 (en)2020-02-242024-02-0610X Genomics, Inc.Methods of making gene expression libraries
US11926863B1 (en)2020-02-272024-03-1210X Genomics, Inc.Solid state single cell method for analyzing fixed biological cells
US11768175B1 (en)2020-03-042023-09-2610X Genomics, Inc.Electrophoretic methods for spatial analysis
WO2021184006A1 (en)*2020-03-132021-09-16Duke UniversityCompositions for the treatment of nash and associated disorders and methods of using same
ES3014967T3 (en)2020-04-222025-04-2810X Genomics IncMethods for spatial analysis using targeted rna depletion
WO2021236625A1 (en)2020-05-192021-11-2510X Genomics, Inc.Electrophoresis cassettes and instrumentation
EP4414459B1 (en)2020-05-222025-09-0310X Genomics, Inc.Simultaneous spatio-temporal measurement of gene expression and cellular activity
AU2021275906A1 (en)2020-05-222022-12-2210X Genomics, Inc.Spatial analysis to detect sequence variants
WO2021242834A1 (en)2020-05-262021-12-0210X Genomics, Inc.Method for resetting an array
US12265079B1 (en)2020-06-022025-04-0110X Genomics, Inc.Systems and methods for detecting analytes from captured single biological particles
EP4025692A2 (en)2020-06-022022-07-1310X Genomics, Inc.Nucleic acid library methods
EP4158054B1 (en)2020-06-022025-04-1610X Genomics, Inc.Spatial transcriptomics for antigen-receptors
US12031177B1 (en)2020-06-042024-07-0910X Genomics, Inc.Methods of enhancing spatial resolution of transcripts
EP4162074B1 (en)2020-06-082024-04-2410X Genomics, Inc.Methods of determining a surgical margin and methods of use thereof
US12435363B1 (en)2020-06-102025-10-0710X Genomics, Inc.Materials and methods for spatial transcriptomics
EP4446430A3 (en)2020-06-102024-12-1810X Genomics, Inc.Methods for determining a location of an analyte in a biological sample
AU2021294334A1 (en)2020-06-252023-02-0210X Genomics, Inc.Spatial analysis of DNA methylation
WO2021262919A2 (en)2020-06-262021-12-30The Research Foundation For The State University Of New York5-halouracil-modified micrornas and their use in the treatment of cancer
US11761038B1 (en)2020-07-062023-09-1910X Genomics, Inc.Methods for identifying a location of an RNA in a biological sample
US11981960B1 (en)2020-07-062024-05-1410X Genomics, Inc.Spatial analysis utilizing degradable hydrogels
US12209280B1 (en)2020-07-062025-01-2810X Genomics, Inc.Methods of identifying abundance and location of an analyte in a biological sample using second strand synthesis
US11981958B1 (en)2020-08-202024-05-1410X Genomics, Inc.Methods for spatial analysis using DNA capture
CN112190592B (zh)*2020-08-252022-03-11苏州市立医院(北区)miRNA在制备防治骨关节炎药物的应用、miRNA高表达的外泌体和应用
EP4491742A3 (en)2020-09-182025-05-2110x Genomics, Inc.Sample handling apparatus and image registration methods
US11926822B1 (en)2020-09-232024-03-1210X Genomics, Inc.Three-dimensional spatial analysis
WO2022076774A2 (en)*2020-10-082022-04-14The Trustees Of Columbia University In The City Of New YorkTreatment and detection of liver fibrosis and liver disease using microrna
CN112375823B (zh)*2020-10-222022-09-16上海交通大学医学院附属瑞金医院miRNA抑制剂在制备治疗和/或预防淋巴瘤的药物中的应用
US11827935B1 (en)2020-11-192023-11-2810X Genomics, Inc.Methods for spatial analysis using rolling circle amplification and detection probes
AU2021409136A1 (en)2020-12-212023-06-2910X Genomics, Inc.Methods, compositions, and systems for capturing probes and/or barcodes
WO2022178218A1 (en)2021-02-192022-08-25Mevion Medical Systems, Inc.Gantry for a particle therapy system
WO2022178267A2 (en)2021-02-192022-08-2510X Genomics, Inc.Modular assay support devices
EP4524261A3 (en)2021-03-182025-05-1410X Genomics, Inc.Multiplex capture of gene and protein expression from a biological sample
EP4305196B1 (en)2021-04-142025-04-0210X Genomics, Inc.Methods of measuring mislocalization of an analyte
EP4320271B1 (en)2021-05-062025-03-1910X Genomics, Inc.Methods for increasing resolution of spatial analysis
EP4347879B1 (en)2021-06-032025-02-1910X Genomics, Inc.Methods, compositions, kits, and systems for enhancing analyte capture for spatial analysis
WO2022272269A1 (en)*2021-06-222022-12-29The Curators Of The University Of MissouriMultianalyte biomarkers for lung cancer
EP4196605B1 (en)2021-09-012024-12-0410X Genomics, Inc.Methods for blocking a capture probe on a spatial array
EP4419707A1 (en)2021-11-102024-08-2810X Genomics, Inc.Methods, compositions, and kits for determining the location of an analyte in a biological sample
EP4305195A2 (en)2021-12-012024-01-1710X Genomics, Inc.Methods, compositions, and systems for improved in situ detection of analytes and spatial analysis
EP4441711A1 (en)2021-12-202024-10-0910X Genomics, Inc.Self-test for pathology/histology slide imaging device
WO2023118546A2 (en)2021-12-232023-06-29Boehringer Ingelheim International GmbhMETHODS AND MOLECULES FOR RNA INTERFERENCE (RNAi)
US11541116B1 (en)2022-01-072023-01-03Kojin Therapeutics, Inc.Methods and compositions for inducing ferroptosis in vivo
WO2024108031A2 (en)*2022-11-162024-05-23University Of Notre Dame Du LacMirna cocktail for treatment and prevention of fibrosis
KR102583230B1 (ko)*2023-03-162023-09-27재단법인 전남바이오산업진흥원뇌경색 예방 또는 치료용 조성물

Family Cites Families (497)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US2007A (en)*1841-03-16Improvement in the mode of harvesting grain
US2006A (en)*1841-03-16Clamp for crimping leather
US1529202A (en)1924-07-161925-03-10Joseph H MillerFestooning machine for carrying paper and the like
GB1529202A (en)1976-02-201978-10-18Ciba Geigy AgSpectral sensitising dyes
US5583013A (en)1977-11-081996-12-10Genentech, Inc.Method and means for microbial polypeptide expression
US5221619A (en)1977-11-081993-06-22Genentech, Inc.Method and means for microbial polypeptide expression
US4704362A (en)1977-11-081987-11-03Genentech, Inc.Recombinant cloning vehicle microbial polypeptide expression
JPS55116259A (en)1979-03-011980-09-06Fuji Photo Film Co LtdMicroimmunoassay method
JPS5745460A (en)1980-09-021982-03-15Fuji Photo Film Co LtdInspection sheet for measuring trace component and inspecting method using said sheet
EP0047472B1 (en)1980-09-021985-04-24Fuji Photo Film Co., Ltd.Method for immunochemical measurement of trace components
NL8200523A (nl)1982-02-111983-09-01Univ LeidenWerkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna.
US4849513A (en)1983-12-201989-07-18California Institute Of TechnologyDeoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups
US4828979A (en)1984-11-081989-05-09Life Technologies, Inc.Nucleotide analogs for nucleic acid labeling and detection
US4683195A (en)*1986-01-301987-07-28Cetus CorporationProcess for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en)1985-03-281987-07-28Cetus CorporationProcess for amplifying nucleic acid sequences
DE3529478A1 (de)1985-08-161987-02-19Boehringer Mannheim Gmbh7-desaza-2'desoxyguanosin-nukleotide, verfahren zu deren herstellung und deren verwendung zur nukleinsaeure-sequenzierung
US4682195A (en)1985-09-301987-07-21General Electric CompanyInsulated gate device with configured emitter contact pad
US4959463A (en)1985-10-151990-09-25Genentech, Inc.Intermediates
US4659774A (en)1985-11-011987-04-21American Hoechst CorporationSupport for solid-phase oligonucleotide synthesis
US4876187A (en)1985-12-051989-10-24Meiogenics, Inc.Nucleic acid compositions with scissile linkage useful for detecting nucleic acid sequences
US5011769A (en)*1985-12-051991-04-30Meiogenics U.S. Limited PartnershipMethods for detecting nucleic acid sequences
US4910300A (en)1985-12-111990-03-20Chiron CorporationMethod for making nucleic acid probes
CA1284931C (en)1986-03-131991-06-18Henry A. ErlichProcess for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
US5268486A (en)1986-04-181993-12-07Carnegie-Mellon UnversityMethod for labeling and detecting materials employing arylsulfonate cyanine dyes
EP0266032A1 (en)1986-08-291988-05-04Beecham Group PlcModified fibrinolytic enzyme
US5202231A (en)1987-04-011993-04-13Drmanac Radoje TMethod of sequencing of genomes by hybridization of oligonucleotide probes
US5525464A (en)1987-04-011996-06-11Hyseq, Inc.Method of sequencing by hybridization of oligonucleotide probes
US4816571A (en)1987-06-041989-03-28Applied Biosystems, Inc.Chemical capping by phosphitylation during oligonucleotide synthesis
GB8803000D0 (en)1988-02-101988-03-09Ekins Roger PhilipDetermination of ambient concentrations of several analytes
US5824311A (en)1987-11-301998-10-20Trustees Of The University Of PennsylvaniaTreatment of tumors with monoclonal antibodies against oncogene antigens
US4952500A (en)1988-02-011990-08-28University Of Georgia Research Foundation, Inc.Cloning systems for Rhodococcus and related bacteria
GB8810400D0 (en)1988-05-031988-06-08Southern EAnalysing polynucleotide sequences
US4999290A (en)*1988-03-311991-03-12The Board Of Regents, The University Of Texas SystemDetection of genomic abnormalities with unique aberrant gene transcripts
US5700637A (en)1988-05-031997-12-23Isis Innovation LimitedApparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5602244A (en)1988-05-261997-02-11Competitive Technologies, Inc.Polynucleotide phosphorodithioate compounds
GB8822228D0 (en)1988-09-211988-10-26Southern E MSupport-bound oligonucleotides
US5708154A (en)1989-02-241998-01-13City Of HopeRNA-DNA hybrid molecules of nucleic acid
US5703055A (en)1989-03-211997-12-30Wisconsin Alumni Research FoundationGeneration of antibodies through lipid mediated DNA delivery
US6867195B1 (en)1989-03-212005-03-15Vical IncorporatedLipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
US5871928A (en)1989-06-071999-02-16Fodor; Stephen P. A.Methods for nucleic acid analysis
US5242974A (en)1991-11-221993-09-07Affymax Technologies N.V.Polymer reversal on solid surfaces
US5800992A (en)1989-06-071998-09-01Fodor; Stephen P.A.Method of detecting nucleic acids
US5143854A (en)1989-06-071992-09-01Affymax Technologies N.V.Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5527681A (en)1989-06-071996-06-18Affymax Technologies N.V.Immobilized molecular synthesis of systematically substituted compounds
US5744101A (en)1989-06-071998-04-28Affymax Technologies N.V.Photolabile nucleoside protecting groups
US6040138A (en)1995-09-152000-03-21Affymetrix, Inc.Expression monitoring by hybridization to high density oligonucleotide arrays
US5547839A (en)1989-06-071996-08-20Affymax Technologies N.V.Sequencing of surface immobilized polymers utilizing microflourescence detection
US5424186A (en)1989-06-071995-06-13Affymax Technologies N.V.Very large scale immobilized polymer synthesis
US5302523A (en)1989-06-211994-04-12Zeneca LimitedTransformation of plant cells
DE3924454A1 (de)1989-07-241991-02-07Cornelis P Prof Dr HollenbergDie anwendung von dna und dna-technologie fuer die konstruktion von netzwerken zur verwendung in der chip-konstruktion und chip-produktion (dna chips)
US7705215B1 (en)1990-04-172010-04-27Dekalb Genetics CorporationMethods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5550318A (en)1990-04-171996-08-27Dekalb Genetics CorporationMethods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5141813A (en)1989-08-281992-08-25Clontech Laboratories, Inc.Multifunctional controlled pore glass reagent for solid phase oligonucleotide synthesis
GB8920097D0 (en)1989-09-061989-10-18Ici PlcAmplification processes
US5545522A (en)1989-09-221996-08-13Van Gelder; Russell N.Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
US5366860A (en)1989-09-291994-11-22Applied Biosystems, Inc.Spectrally resolvable rhodamine dyes for nucleic acid sequence determination
US5322783A (en)1989-10-171994-06-21Pioneer Hi-Bred International, Inc.Soybean transformation by microparticle bombardment
DK0497875T3 (da)1989-10-242000-07-03Gilead Sciences Inc2'-modificerede oligonukleotider
US5188934A (en)*1989-11-141993-02-23Applied Biosystems, Inc.4,7-dichlorofluorescein dyes as molecular probes
EP0430881A3 (en)1989-11-291991-10-23Ciba-Geigy AgPhotochromic compounds, process for their preparation and their use
US5486603A (en)*1990-01-081996-01-23Gilead Sciences, Inc.Oligonucleotide having enhanced binding affinity
US5859221A (en)1990-01-111999-01-12Isis Pharmaceuticals, Inc.2'-modified oligonucleotides
US6153737A (en)1990-01-112000-11-28Isis Pharmaceuticals, Inc.Derivatized oligonucleotides having improved uptake and other properties
US5670633A (en)1990-01-111997-09-23Isis Pharmaceuticals, Inc.Sugar modified oligonucleotides that detect and modulate gene expression
US5872232A (en)1990-01-111999-02-16Isis Pharmaceuticals Inc.2'-O-modified oligonucleotides
US5484956A (en)1990-01-221996-01-16Dekalb Genetics CorporationFertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
US5214136A (en)1990-02-201993-05-25Gilead Sciences, Inc.Anthraquinone-derivatives oligonucleotides
US5288644A (en)1990-04-041994-02-22The Rockefeller UniversityInstrument and method for the sequencing of genome
US5470967A (en)1990-04-101995-11-28The Dupont Merck Pharmaceutical CompanyOligonucleotide analogs with sulfamate linkages
GB9009980D0 (en)1990-05-031990-06-27Amersham Int PlcPhosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
US5602240A (en)1990-07-271997-02-11Ciba Geigy Ag.Backbone modified oligonucleotide analogs
US5223618A (en)1990-08-131993-06-29Isis Pharmaceuticals, Inc.4'-desmethyl nucleoside analog compounds
US5610289A (en)1990-07-271997-03-11Isis Pharmaceuticals, Inc.Backbone modified oligonucleotide analogues
US5378825A (en)1990-07-271995-01-03Isis Pharmaceuticals, Inc.Backbone modified oligonucleotide analogs
US5623070A (en)1990-07-271997-04-22Isis Pharmaceuticals, Inc.Heteroatomic oligonucleoside linkages
EP0544824B1 (en)1990-07-271997-06-11Isis Pharmaceuticals, Inc.Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
US5432272A (en)*1990-10-091995-07-11Benner; Steven A.Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5965364A (en)1990-10-091999-10-12Benner; Steven AlbertMethod for selecting functional deoxyribonucleotide derivatives
WO1992007095A1 (en)*1990-10-151992-04-30StratageneArbitrarily primed polymerase chain reaction method for fingerprinting genomes
US5384253A (en)1990-12-281995-01-24Dekalb Genetics CorporationGenetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
US5672697A (en)1991-02-081997-09-30Gilead Sciences, Inc.Nucleoside 5'-methylene phosphonates
US6287792B1 (en)1991-06-172001-09-11The Regents Of The University Of CaliforniaDrug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
AU662906B2 (en)1991-06-261995-09-21F. Hoffmann-La Roche AgMethods for detection of carcinoma metastases by nucleic acid amplification
US6369209B1 (en)1999-05-032002-04-09Isis Pharmaceuticals, Inc.Oligonucleotides having A-DNA form and B-DNA form conformational geometry
WO1993004169A1 (en)1991-08-201993-03-04Genpharm International, Inc.Gene targeting in animal cells using isogenic dna constructs
US5639603A (en)1991-09-181997-06-17Affymax Technologies N.V.Synthesizing and screening molecular diversity
US5610042A (en)1991-10-071997-03-11Ciba-Geigy CorporationMethods for stable transformation of wheat
IL103674A0 (en)1991-11-191993-04-04Houston Advanced Res CenterMethod and apparatus for molecule detection
US5324633A (en)1991-11-221994-06-28Affymax Technologies N.V.Method and apparatus for measuring binding affinity
US5384261A (en)1991-11-221995-01-24Affymax Technologies N.V.Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5412087A (en)1992-04-241995-05-02Affymax Technologies N.V.Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US5256555A (en)*1991-12-201993-10-26Ambion, Inc.Compositions and methods for increasing the yields of in vitro RNA transcription and other polynucleotide synthetic reactions
US5700922A (en)1991-12-241997-12-23Isis Pharmaceuticals, Inc.PNA-DNA-PNA chimeric macromolecules
US5260191A (en)1992-01-301993-11-09Agracetus, Inc.Method for diagnosing tumors
US5652099A (en)1992-02-121997-07-29Conrad; Michael J.Probes comprising fluorescent nucleosides and uses thereof
EP0628051B1 (en)1992-02-122003-07-02Chromagen, Inc.Applications of fluorescent n-nucleosides and fluorescent structural analogs of n-nucleosides
DE4204650C1 (es)1992-02-151993-07-08Hoffmeister, Helmut, Dr., 4400 Muenster, De
ATE278807T1 (de)1992-02-192004-10-15New York Health Res InstNeue anordnungen von oligonukleotiden und ihr nutzen zum sortieren, isolieren, sequenzierung und manipulieren von nukleinsäuren
CA2102784A1 (en)1992-03-111993-09-12Peng LiangIdentifying, isolating and cloning messenger rnas
US5262311A (en)1992-03-111993-11-16Dana-Farber Cancer Institute, Inc.Methods to clone polyA mRNA
ATE173767T1 (de)1992-04-031998-12-15Perkin Elmer CorpProben zusammensetzung und verfahren
GB9208545D0 (en)1992-04-211992-06-03Gatsby Charitable Foundation TVirus resistant plants
US5428148A (en)1992-04-241995-06-27Beckman Instruments, Inc.N4 - acylated cytidinyl compounds useful in oligonucleotide synthesis
EP0604662B1 (en)1992-07-072008-06-18Japan Tobacco Inc.Method of transforming monocotyledon
US5702932A (en)1992-07-201997-12-30University Of FloridaMicroinjection methods to transform arthropods with exogenous DNA
AU670316B2 (en)1992-07-271996-07-11Pioneer Hi-Bred International, Inc.An improved method of (agrobacterium)-mediated transformation of cultured soybean cells
US5438131A (en)1992-09-161995-08-01Bergstrom; Donald E.3-nitropyrrole nucleoside
US5554501A (en)1992-10-291996-09-10Beckman Instruments, Inc.Biopolymer synthesis using surface activated biaxially oriented polypropylene
GB9222888D0 (en)1992-10-301992-12-16British Tech GroupTomography
US5503980A (en)1992-11-061996-04-02Trustees Of Boston UniversityPositional sequencing by hybridization
US5858988A (en)1993-02-241999-01-12Wang; Jui H.Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use
US5801005A (en)1993-03-171998-09-01University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5580726A (en)1994-04-291996-12-03Geron CorporationMethod and Kit for enhanced differential display
US5767259A (en)*1994-12-271998-06-16NaxcorOligonucleotides containing base-free linking groups with photoactivatable side chains
US5858659A (en)1995-11-291999-01-12Affymetrix, Inc.Polymorphism detection
US5472672A (en)1993-10-221995-12-05The Board Of Trustees Of The Leland Stanford Junior UniversityApparatus and method for polymer synthesis using arrays
US5470710A (en)1993-10-221995-11-28University Of UtahAutomated hybridization/imaging device for fluorescent multiplex DNA sequencing
US6045996A (en)1993-10-262000-04-04Affymetrix, Inc.Hybridization assays on oligonucleotide arrays
EP0730663B1 (en)1993-10-262003-09-24Affymetrix, Inc.Arrays of nucleic acid probes on biological chips
US5429807A (en)1993-10-281995-07-04Beckman Instruments, Inc.Method and apparatus for creating biopolymer arrays on a solid support surface
US5925517A (en)1993-11-121999-07-20The Public Health Research Institute Of The City Of New York, Inc.Detectably labeled dual conformation oligonucleotide probes, assays and kits
US5538848A (en)*1994-11-161996-07-23Applied Biosystems Division, Perkin-Elmer Corp.Method for detecting nucleic acid amplification using self-quenching fluorescence probe
WO1995014106A2 (en)1993-11-171995-05-26Id Biomedical CorporationCycling probe cleavage detection of nucleic acid sequences
US5610287A (en)1993-12-061997-03-11Molecular Tool, Inc.Method for immobilizing nucleic acid molecules
US5446137B1 (en)1993-12-091998-10-06Behringwerke AgOligonucleotides containing 4'-substituted nucleotides
US5519134A (en)1994-01-111996-05-21Isis Pharmaceuticals, Inc.Pyrrolidine-containing monomers and oligomers
GB9401833D0 (en)1994-02-011994-03-30Isis InnovationMethod for discovering ligands
JPH09508800A (ja)1994-02-141997-09-09スミスクライン・ビーチャム・コーポレイション差次的発現遺伝子の同定法
DE4406524A1 (de)1994-02-281995-08-31Boehringer Mannheim Gmbh3'-RNA-Markierung mit Terminaler Transferase
US5844107A (en)1994-03-231998-12-01Case Western Reserve UniversityCompacted nucleic acids and their delivery to cells
US6077835A (en)1994-03-232000-06-20Case Western Reserve UniversityDelivery of compacted nucleic acid to cells
US5972901A (en)1994-03-231999-10-26Case Western Reserve UniversitySerpin enzyme complex receptor--mediated gene transfer
CA2186118C (en)1994-03-232010-10-19Richard W. HansonCompacted nucleic acids and their delivery to cells
US5571639A (en)1994-05-241996-11-05Affymax Technologies N.V.Computer-aided engineering system for design of sequence arrays and lithographic masks
US5807522A (en)1994-06-171998-09-15The Board Of Trustees Of The Leland Stanford Junior UniversityMethods for fabricating microarrays of biological samples
US5656610A (en)1994-06-211997-08-12University Of Southern CaliforniaProducing a protein in a mammal by injection of a DNA-sequence into the tongue
US6146886A (en)1994-08-192000-11-14Ribozyme Pharmaceuticals, Inc.RNA polymerase III-based expression of therapeutic RNAs
GB9506466D0 (en)1994-08-261995-05-17Prolifix LtdCell cycle regulated repressor and dna element
US5574146A (en)1994-08-301996-11-12Beckman Instruments, Inc.Oligonucleotide synthesis with substituted aryl carboxylic acids as activators
US5554744A (en)1994-09-231996-09-10Hybridon, Inc.Method for loading solid supports for nucleic acid synthesis
US6096314A (en)1994-10-072000-08-01Yeda Research And Development Co. Ltd.Peptides and pharmaceutical compositions comprising them
US5604097A (en)1994-10-131997-02-18Spectragen, Inc.Methods for sorting polynucleotides using oligonucleotide tags
US5556752A (en)1994-10-241996-09-17Affymetrix, Inc.Surface-bound, unimolecular, double-stranded DNA
US5736524A (en)1994-11-141998-04-07Merck & Co.,. Inc.Polynucleotide tuberculosis vaccine
US5830645A (en)1994-12-091998-11-03The Regents Of The University Of CaliforniaComparative fluorescence hybridization to nucleic acid arrays
US5599695A (en)1995-02-271997-02-04Affymetrix, Inc.Printing molecular library arrays using deprotection agents solely in the vapor phase
ATE397097T1 (de)*1995-03-172008-06-15Wayne John Cancer InstNachweis von brustmetastasen unter verwendung eines mehrfachmarker-tests
US5801155A (en)1995-04-031998-09-01Epoch Pharmaceuticals, Inc.Covalently linked oligonucleotide minor grove binder conjugates
GB9507238D0 (en)1995-04-071995-05-31Isis InnovationDetecting dna sequence variations
US5624711A (en)1995-04-271997-04-29Affymax Technologies, N.V.Derivatization of solid supports and methods for oligomer synthesis
DE19518505A1 (de)1995-05-191996-11-21Max Planck GesellschaftVerfahren zur Genexpressionsanalyse
US5981501A (en)1995-06-071999-11-09Inex Pharmaceuticals Corp.Methods for encapsulating plasmids in lipid bilayers
US6111095A (en)1995-06-072000-08-29Merck & Co., Inc.Capped synthetic RNA, analogs, and aptamers
US5545531A (en)1995-06-071996-08-13Affymax Technologies N.V.Methods for making a device for concurrently processing multiple biological chip assays
US5976567A (en)1995-06-071999-11-02Inex Pharmaceuticals Corp.Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6998268B2 (en)1995-07-032006-02-14Dainippon Sumitomo Pharma Co. Ltd.Gene preparations
US5637683A (en)1995-07-131997-06-10Cornell Research Foundation, Inc.Nucleic acid analog with amide linkage and method of making that analog
US5661028A (en)1995-09-291997-08-26Lockheed Martin Energy Systems, Inc.Large scale DNA microsequencing device
US5658734A (en)1995-10-171997-08-19International Business Machines CorporationProcess for synthesizing chemical compounds
US5705629A (en)1995-10-201998-01-06Hybridon, Inc.Methods for H-phosphonate synthesis of mono- and oligonucleotides
US6418382B2 (en)*1995-10-242002-07-09Curagen CorporationMethod and apparatus for identifying, classifying, or quantifying DNA sequences in a sample without sequencing
US5871697A (en)*1995-10-241999-02-16Curagen CorporationMethod and apparatus for identifying, classifying, or quantifying DNA sequences in a sample without sequencing
US20040142895A1 (en)1995-10-262004-07-22Sirna Therapeutics, Inc.Nucleic acid-based modulation of gene expression in the vascular endothelial growth factor pathway
US5780448A (en)1995-11-071998-07-14Ottawa Civic Hospital Loeb ResearchDNA-based vaccination of fish
US5998203A (en)*1996-04-161999-12-07Ribozyme Pharmaceuticals, Inc.Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
AU2253397A (en)1996-01-231997-08-20Affymetrix, Inc.Nucleic acid analysis techniques
EP0880598A4 (en)*1996-01-232005-02-23Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
US5837196A (en)1996-01-261998-11-17The Regents Of The University Of CaliforniaHigh density array fabrication and readout method for a fiber optic biosensor
US5670663A (en)1996-02-141997-09-23Regents Of The University Of CaliforniaRecovery of taxanes from conifers
US6020481A (en)*1996-04-012000-02-01The Perkin-Elmer CorporationAsymmetric benzoxanthene dyes
US6458530B1 (en)1996-04-042002-10-01Affymetrix Inc.Selecting tag nucleic acids
AU713667B2 (en)1996-04-121999-12-09Phri Properties, Inc.Detection probes, kits and assays
US5847162A (en)1996-06-271998-12-08The Perkin Elmer Corporation4, 7-Dichlororhodamine dyes
US5863727A (en)*1996-05-031999-01-26The Perkin-Elmer CorporationEnergy transfer dyes with enhanced fluorescence
US5800996A (en)1996-05-031998-09-01The Perkin Elmer CorporationEnergy transfer dyes with enchanced fluorescence
US5945526A (en)1996-05-031999-08-31Perkin-Elmer CorporationEnergy transfer dyes with enhanced fluorescence
US6184037B1 (en)1996-05-172001-02-06Genemedicine, Inc.Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell
SE506700C2 (sv)1996-05-311998-02-02Mikael KubistaSond och förfaranden för analys av nukleinsyra
US5739169A (en)*1996-05-311998-04-14Procept, IncorporatedAromatic compounds for inhibiting immune response
NZ333136A (en)*1996-06-042000-03-27Univ Utah Res FoundContinuous monitoring of hybridization during PCR using fluorescence resonance energy transfer pairs
US5898031A (en)*1996-06-061999-04-27Isis Pharmaceuticals, Inc.Oligoribonucleotides for cleaving RNA
US5945100A (en)1996-07-311999-08-31Fbp CorporationTumor delivery vehicles
US6770291B2 (en)1996-08-302004-08-03The United States Of America As Represented By The Department Of Health And Human ServicesLiposome complexes for increased systemic delivery
GB9618050D0 (en)1996-08-291996-10-09Cancer Res Campaign TechGlobal amplification of nucleic acids
US5981274A (en)1996-09-181999-11-09Tyrrell; D. Lorne J.Recombinant hepatitis virus vectors
US5886165A (en)1996-09-241999-03-23Hybridon, Inc.Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments
ES2331388T3 (es)1997-03-072009-12-30Siemens Healthcare Diagnostics Inc.Marcador especifico para el cancer de prostata.
ID21013A (id)1997-03-101999-04-08Japan Tobacco IncDeret nukleotida antipeka
US6251666B1 (en)1997-03-312001-06-26Ribozyme Pharmaceuticals, Inc.Nucleic acid catalysts comprising L-nucleotide analogs
US6090556A (en)1997-04-072000-07-18Japan Science & Technology CorporationMethod for quantitatively determining the expression of a gene
NO972006D0 (no)1997-04-301997-04-30Forskningsparken I Aas AsNy metode for diagnose av sykdommer
EP1027033B1 (en)1997-05-142009-07-22The University Of British ColumbiaHigh efficiency encapsulation of nucleic acids in lipid vesicles
US6262252B1 (en)1997-05-192001-07-17Mirus, Inc.Single-step method for labeling nucleic acids with mustard or aziridine labeling reagents
US5919626A (en)1997-06-061999-07-06Orchid Bio Computer, Inc.Attachment of unmodified nucleic acids to silanized solid phase surfaces
JP3693352B2 (ja)1997-06-132005-09-07アフィメトリックス インコーポレイテッドプローブアレイを使用して、遺伝子多型性を検出し、対立遺伝子発現をモニターする方法
US6008379A (en)1997-10-011999-12-28The Perkin-Elmer CorporationAromatic-substituted xanthene dyes
US5994624A (en)1997-10-201999-11-30Cotton IncorporatedIn planta method for the production of transgenic plants
US6485901B1 (en)1997-10-272002-11-26Boston Probes, Inc.Methods, kits and compositions pertaining to linear beacons
DE69841849D1 (de)*1997-10-272010-09-30Boston Probes IncSich auf "pna molecular beacons" beziehende verfahren, testsätze und zusammensetzungen
AU753505B2 (en)1997-10-302002-10-17Cold Spring Harbor LaboratoryProbe arrays and methods of using probe arrays for distinguishing DNA
US5936087A (en)1997-11-251999-08-10The Perkin-Elmer CorporationDibenzorhodamine dyes
US6238869B1 (en)*1997-12-192001-05-29High Throughput Genomics, Inc.High throughput assay system
US6458533B1 (en)1997-12-192002-10-01High Throughput Genomics, Inc.High throughput assay system for monitoring ESTs
US6232066B1 (en)*1997-12-192001-05-15Neogen, Inc.High throughput assay system
US6506559B1 (en)1997-12-232003-01-14Carnegie Institute Of WashingtonGenetic inhibition by double-stranded RNA
US6121058A (en)1998-01-022000-09-19Intel CorporationMethod for removing accumulated solder from probe card probing features
US6087102A (en)1998-01-072000-07-11Clontech Laboratories, Inc.Polymeric arrays and methods for their use in binding assays
US6269846B1 (en)1998-01-132001-08-07Genetic Microsystems, Inc.Depositing fluid specimens on substrates, resulting ordered arrays, techniques for deposition of arrays
US5942398A (en)1998-02-261999-08-24Millennium Pharmaceuticals, Inc.Nucleic acid molecules encoding glutx and uses thereof
AUPP249298A0 (en)1998-03-201998-04-23Ag-Gene Australia LimitedSynthetic genes and genetic constructs comprising same I
US6004755A (en)1998-04-071999-12-21Incyte Pharmaceuticals, Inc.Quantitative microarray hybridizaton assays
CA2326823A1 (en)1998-04-201999-10-28Ribozyme Pharmaceuticals, Inc.Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
US6037129A (en)*1998-05-282000-03-14Medical University Of South CarolinaMulti-marker RT-PCR panel for detecting metastatic breast cancer
FR2780059B1 (fr)1998-06-172002-10-11Bio MerieuxProcede de marquage d'un acide ribonucleique et fragments d'arn marques ainsi obtenus
US6576420B1 (en)1998-06-232003-06-10Regents Of The University Of CaliforniaMethod for early diagnosis of, and determination of prognosis in, cancer
GB9815799D0 (en)1998-07-211998-09-16Pharmagene Lab LimitedQuantitative analysis of gene expression
US6730477B1 (en)*1998-08-042004-05-04Diadexus, Inc.Method of diagnosing, monitoring and staging breast cancer
US6140054A (en)1998-09-302000-10-31University Of Utah Research FoundationMultiplex genotyping using fluorescent hybridization probes
WO2000024939A1 (en)1998-10-272000-05-04Affymetrix, Inc.Complexity management and analysis of genomic dna
DE19956568A1 (de)1999-01-302000-08-17Roland KreutzerVerfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
GB9904991D0 (en)*1999-03-051999-04-28Univ NottinghamGenetic screening
CA2368135C (en)1999-03-182010-06-08Exiqon A/SXylo-lna analogues
US6383752B1 (en)*1999-03-312002-05-07Hybridon, Inc.Pseudo-cyclic oligonucleobases
US6103576A (en)*1999-04-132000-08-15Microchip Technology IncorporatedDielectric layer of a memory cell having a stacked oxide sidewall and method of fabricating same
US7053207B2 (en)1999-05-042006-05-30Exiqon A/SL-ribo-LNA analogues
US6638717B2 (en)1999-05-192003-10-28Aventis Pharmaceuticals, Inc.Microarray-based subtractive hybridzation
DE60030970T2 (de)1999-05-242007-09-06Introgen Therapeutics Inc., AustinVerfahren und zusammensetzungen für nichtvirale gentherapie zur behandlung von hyperproliferativen krankheiten
US6132997A (en)1999-05-282000-10-17Agilent TechnologiesMethod for linear mRNA amplification
AU780454B2 (en)1999-06-032005-03-24Jessie L.S. AuMethods and compositions for modulating cell proliferation and cell death
WO2000075356A1 (en)1999-06-042000-12-14Lin Shi LungRna polymerase chain reaction
US6964847B1 (en)1999-07-142005-11-15Packard Biosciences CompanyDerivative nucleic acids and uses thereof
US6201112B1 (en)1999-07-222001-03-13Agilent Technologies Inc.Method for 3′ end-labeling ribonucleic acids
US7005261B1 (en)*1999-07-292006-02-28British Biocell International LimitedMethod for detecting nucleic acid target sequences involving in vitro transcription from an RNA polymerase promoter
US6140500A (en)1999-09-032000-10-31Pe CorporationRed-emitting [8,9]benzophenoxazine nucleic acid dyes and methods for their use
US6511832B1 (en)*1999-10-062003-01-28Texas A&M University SystemIn vitro synthesis of capped and polyadenylated mRNAs using baculovirus RNA polymerase
US20020094546A1 (en)1999-10-072002-07-18Shimkets Richard A.Growth factor polypeptides and nucleic acids encoding same
EP1235842A4 (en)1999-10-152003-04-23Univ MassachusettsRna interference pathway genes as tools for targeted genetic interference
US6528254B1 (en)*1999-10-292003-03-04StratageneMethods for detection of a target nucleic acid sequence
US6191278B1 (en)*1999-11-032001-02-20Pe CorporationWater-soluble rhodamine dyes and conjugates thereof
US6458382B1 (en)1999-11-122002-10-01Mirus CorporationNucleic acid transfer complexes
US6435245B1 (en)1999-11-182002-08-20Pitney Bowes Inc.System for folding and tabbing sheets
GB9927444D0 (en)1999-11-192000-01-19Cancer Res Campaign TechInhibiting gene expression
DE10160151A1 (de)2001-01-092003-06-26Ribopharma AgVerfahren zur Hemmung der Expression eines vorgegebenen Zielgens
DE10100586C1 (de)2001-01-092002-04-11Ribopharma AgVerfahren zur Hemmung der Expression eines Ziegens
WO2001038580A2 (en)1999-11-262001-05-31Curagen CorporationNucleic acid probe arrays
US6383749B2 (en)1999-12-022002-05-07Clontech Laboratories, Inc.Methods of labeling nucleic acids for use in array based hybridization assays
US7205105B2 (en)*1999-12-082007-04-17Epoch Biosciences, Inc.Real-time linear detection probes: sensitive 5′-minor groove binder-containing probes for PCR analysis
AU2001234608A1 (en)2000-01-282001-08-07Genetrace Systems, Inc.Methods for analysis of gene expression
US8202979B2 (en)*2002-02-202012-06-19Sirna Therapeutics, Inc.RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
WO2002081628A2 (en)2001-04-052002-10-17Ribozyme Pharmaceuticals, IncorporatedModulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
US20020065406A1 (en)2000-03-242002-05-30Meyers Rachel A.18221, a novel dual specificity phosphatase and uses thereof
US6447723B1 (en)2000-03-132002-09-10Packard Instrument Company, Inc.Microarray spotting instruments incorporating sensors and methods of using sensors for improving performance of microarray spotting instruments
US20030084471A1 (en)*2000-03-162003-05-01David BeachMethods and compositions for RNA interference
WO2001070095A2 (en)2000-03-232001-09-27Diadexus, Inc.Compositions and methods of diagnosing, monitoring, staging, imaging and treating prostate cancer
WO2001072780A2 (en)2000-03-272001-10-04Diadexus, Inc.Polynucleotides for diagnosing mammary gland cancer
WO2001073030A2 (en)2000-03-282001-10-04Diadexus, Inc.Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
WO2001072775A2 (en)2000-03-292001-10-04Diadexus, Inc.Polynucleotides and polypeptides as well as methods for diagnosing and treating lung cancer
PT1309726E (pt)*2000-03-302010-03-08Whitehead Biomedical InstMediadores de interferência por rna específicos de sequência de rna
US20020068307A1 (en)2000-03-302002-06-06Jason PlutaCompositions and methods for diagnosing, monitoring, staging, imaging and treating stomach cancer
US6573048B1 (en)*2000-04-182003-06-03NaxcorDegradable nucleic acid probes and nucleic acid detection methods
EP2359857A3 (en)2000-05-102012-02-22Signe BioPharma Inc.Compositions and methods for demonstrating secretory immune system regulation of steroid hormone responsive cancer cell growth
US20020042388A1 (en)2001-05-012002-04-11Cooper Mark J.Lyophilizable and enhanced compacted nucleic acids
WO2001091805A2 (en)2000-06-022001-12-06Bracco Research UsaCompounds for targeting endothelial cells
WO2002000169A2 (en)2000-06-262002-01-03The United States Of America, As Represented By The Secretary Of AgricultureProduction of vaccines using transgenic plants
WO2002000926A2 (en)2000-06-302002-01-03Epigenomics AgDiagnosis of diseases associated with signal transduction
US6596490B2 (en)*2000-07-142003-07-22Applied Gene Technologies, Inc.Nucleic acid hairpin probes and uses thereof
DK1325008T3 (da)2000-07-312006-02-13Hoffmann La RochePiperazinderivater
US6797471B2 (en)2000-08-042004-09-28Board Of Regents, The University Of Texas SystemDetection and diagnosis of smoking related cancers
JP2002067789A (ja)*2000-09-052002-03-08Yazaki Corpランプユニットの電線接続構造
AU2001292842A1 (en)2000-09-192002-04-02Diadexus, Inc.Compositions and methods relating to prostate specific genes and proteins
US20030082604A1 (en)2000-09-272003-05-01Swanson Melvin J.High density arrays
US6350580B1 (en)*2000-10-112002-02-26StratageneMethods for detection of a target nucleic acid using a probe comprising secondary structure
US6617112B2 (en)2000-10-112003-09-09Monsanto Technology LlcMethods for gene array analysis of nuclear runoff transcripts
US7162371B1 (en)2000-10-112007-01-09Georgia Tech Research CorporationDifferentially-expressed conifer cDNAs, and their use in improving somatic embryogenesis
WO2002032396A2 (en)2000-10-162002-04-25Massachusetts Institute Of TechnologyLipid-protein-sugar particles for delivery of nucleic acids
AU2002243429A1 (en)*2000-10-242002-06-24Isis Pharmaceuticals, Inc.Antisense modulation of tnfr1 expression
US7001724B1 (en)*2000-11-282006-02-21Applera CorporationCompositions, methods, and kits for isolating nucleic acids using surfactants and proteases
GB0029360D0 (en)2000-12-012001-01-17Univ NottinghamHumanised antibodies and uses thereof
CA2429814C (en)2000-12-012014-02-18Thomas TuschlRna interference mediating small rna molecules
NZ543940A (en)2000-12-042008-04-30Primagen B VDetermining the ratio of genomic DNA and mtDNA or their related gene products with regards to determining the stage of an asymptomatic disease
US20030099976A1 (en)2001-01-172003-05-29Tai-Jay ChangAndrogen receptor complex-associated protein
US20040115671A1 (en)2001-01-182004-06-17Zlokovic Berislav VGene expression profiling of endothelium in alzheimer's disease
US7015047B2 (en)*2001-01-262006-03-21Aviva Biosciences CorporationMicrodevices having a preferential axis of magnetization and uses thereof
US20040058373A1 (en)*2001-01-312004-03-25Winkler Matthew M.Competitive amplification of fractionated targets from multiple nucleic acid samples
WO2002064835A2 (en)2001-01-312002-08-22Ambion, Inc.Methods for nucleic acid fingerprint analysis
US20040110191A1 (en)*2001-01-312004-06-10Winkler Matthew M.Comparative analysis of nucleic acids using population tagging
WO2002073504A1 (en)2001-03-142002-09-19Gene Logic, Inc.A system and method for retrieving and using gene expression data from multiple sources
US20030170623A1 (en)2001-04-132003-09-11Jingwen ChenMultiplexed gene analysis on a mobile solid support
EP1390387A4 (en)2001-04-202004-12-08Ludwig Inst Cancer Res TESTICLES CANCER ANTIGENS
CA2445532A1 (en)2001-04-272002-11-07Sunnybrook & Women's College Health Sciences CentreBreast cancer-associated genes and uses thereof
US20030203865A1 (en)2001-04-302003-10-30Pierrot HarvieLipid-comprising drug delivery complexes and methods for their production
AUPR480901A0 (en)2001-05-042001-05-31Genomics Research Partners Pty LtdDiagnostic method for assessing a condition of a performance animal
WO2003070917A2 (en)*2002-02-202003-08-28Sirna Therapeutics, Inc.Rna interference mediated inhibition of myc and myb genes or genes of their respective pathways
US20040209832A1 (en)2001-11-302004-10-21Mcswiggen JamesRNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
EP1399868A2 (en)2001-06-012004-03-24Prosanos CorporationInformation processing method for disease stratification and assessment of disease progressing
US7171311B2 (en)*2001-06-182007-01-30Rosetta Inpharmatics LlcMethods of assigning treatment to breast cancer patients
US20040086504A1 (en)2001-06-212004-05-06Deepak SampathCyr61 as a target for treatment and diagnosis of breast cancer
US20040215651A1 (en)2001-06-222004-10-28Markowitz Victor M.Platform for management and mining of genomic data
AU2002346008A1 (en)2001-06-282003-03-03Dermtech InternationalMethod for detection of melanoma
NZ530451A (en)2001-06-292008-04-30Univ Leland Stanford JuniorTIM gene sequences and their use in immunological disorders and cancer
WO2003087297A2 (en)2001-08-082003-10-23North Carolina State UniversityInfectious disease microarray
AU2002331777A1 (en)2001-08-302003-03-18Spectral Genomics, Inc.Arrays comprising pre-labeled biological molecules and methods for making and using these arrays
US20030198627A1 (en)*2001-09-012003-10-23Gert-Jan ArtssiRNA knockout assay method and constructs
WO2003021227A2 (en)2001-09-052003-03-13The Children's Hospital Of PhiladelphiaMethods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
EP1423542A2 (en)2001-09-062004-06-02MERCK PATENT GmbHGenetic analysis of biological samples in arrayed expanded representations of their nucleic acids
WO2003022421A2 (en)2001-09-072003-03-20Corning IncorporatedMicrocolumn-platform based array for high-throughput analysis
JP4439262B2 (ja)*2001-09-192010-03-24アレクシオン ファーマシューティカルズ， インコーポレイテッド操作されたテンプレートおよび単一プライマー増幅におけるそれらの使用
WO2003024388A2 (en)*2001-09-202003-03-27Cornell Research Foundation, Inc.Methods and compositions for treating and preventing skin disorders using binding agents specific for psma
US6593091B2 (en)*2001-09-242003-07-15Beckman Coulter, Inc.Oligonucleotide probes for detecting nucleic acids through changes in flourescence resonance energy transfer
WO2003029459A2 (en)*2001-09-282003-04-10MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.Micro-rna molecules
WO2003029485A2 (en)2001-10-022003-04-10Azign Bioscience A/SSpecific differential display arrays
AU2002367886B8 (en)2001-10-122008-08-14Perkinelmer Las, Inc.Compilations of nucleic acids and arrays and methods of using them
US20040063654A1 (en)*2001-11-022004-04-01Davis Mark E.Methods and compositions for therapeutic use of RNA interference
EP2325193A3 (en)2001-11-022012-05-02Insert Therapeutics, Inc.Methods and compositions for therapeutic use of RNA interference
WO2003040410A1 (en)2001-11-022003-05-15Nimblegen Systems, Inc.Detection of hybridization oligonucleotide microarray through covalently labeling microarray probe
JP2005516183A (ja)2001-11-192005-06-02プロトメトリックス，インコーポレーテッド検体を検出および測定するための非抗体タンパク質の使用方法
US20030157700A1 (en)2001-12-192003-08-21Affymetrix, Inc.Apparatus and methods for constructing array plates
EP1465997A4 (en)*2001-12-272006-05-24Agy Therapeutics Inc USE OF BIOMOLECULAR OBJECTIVES IN THE TREATMENT AND VISUALIZATION OF TUMORS
US7141372B2 (en)2002-01-182006-11-28Health Research IncorporatedUniversal RT-coupled PCR method for the specific amplification of mRNA
US20030215842A1 (en)2002-01-302003-11-20Epigenomics AgMethod for the analysis of cytosine methylation patterns
US20030148362A1 (en)2002-02-072003-08-07Eastern Virginia Medical School Of The Medical College Of Hampton RoadsDiagnostic microarray and method of use thereof
WO2003067217A2 (en)2002-02-082003-08-14Integriderm, Inc.Skin cell biomarkers and methods for identifying biomarkers using nucleic acid microarrays
US20060088831A1 (en)2002-03-072006-04-27University Of Utah Research FoundationMethods for identifying large subsets of differentially expressed genes based on multivariate microarray data analysis
US20070025997A1 (en)2002-04-032007-02-01Usha NagavarapuUse of biomolecular targets in the treatment and visualization of brain tumors
AU2003230807B2 (en)2002-04-032008-03-13Medarex, Inc.Use of biomolecular targets in the treatment and visualization of brain tumors
US7006680B2 (en)2002-05-032006-02-28Vialogy Corp.System and method for characterizing microarray output data
EP1504126B1 (en)2002-05-032014-02-26Duke UniversityA method of regulating gene expression
AU2003239506B2 (en)2002-05-202007-08-02Northrop Grumman CorporationAutomatic point source biological agent detection system
JP4544989B2 (ja)2002-05-242010-09-15ニンブルゲン システムズ インコーポレイテッド単一マイクロアレイ上で多数の試料のハイブリダイゼーション反応を行うマイクロアレイ及びその方法
AUPS261402A0 (en)2002-05-282002-06-20Compusign Pty LtdArray monitoring
US20030228579A1 (en)2002-06-052003-12-11Uri AlonOrdering genes by analysis of expression kinetics
EP2258847B2 (en)2002-08-052020-07-01Silence Therapeutics GmbHFuther novel forms of interfering RNA molecules
WO2004014933A1 (en)*2002-08-072004-02-19University Of MassachusettsCompositions for rna interference and methods of use thereof
US20040029128A1 (en)2002-08-082004-02-12Epigenomics, Inc.Methods and nucleic acids for the analysis of CpG dinucleotide methylation status associated with the calcitonin gene
US20040029121A1 (en)2002-08-082004-02-12Susan CottrellMethods and nucleic acids for the analysis of CpG dinucleotide methylation status associated with the calcitonin gene
EP1560924A4 (en)2002-08-162006-05-31Wayne John Cancer Inst MOLECULAR LYMPHATIC MAPPING OF VIRCHOV LYMPHOTIC NODES
US20040114800A1 (en)2002-09-122004-06-17Baylor College Of MedicineSystem and method for image segmentation
AU2003267583A1 (en)2002-09-192004-04-08The Chancellor, Master And Scholars Of The University Of OxfordMolecular arrays and single molecule detection
WO2004029212A2 (en)2002-09-252004-04-08University Of MassachusettsIn vivo gene silencing by chemically modified and stable sirna
ATE455185T1 (de)2002-11-012010-01-15Univ New York State Res FoundAtypische protein-kinase-c-isoformen bei erkrankungen des nervensystems und krebs
EP1418241A1 (en)2002-11-082004-05-12PrimaGen Holding B.V.Method for quantifying a ratio between at least two nucleic acid sequences
AU2003291433B2 (en)2002-11-132008-05-22Thomas Jefferson UniversityCompositions and methods for cancer diagnosis and therapy
US7655785B1 (en)2002-11-142010-02-02Rosetta Genomics Ltd.Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
US7250496B2 (en)*2002-11-142007-07-31Rosetta Genomics Ltd.Bioinformatically detectable group of novel regulatory genes and uses thereof
WO2004046324A2 (en)2002-11-152004-06-03University Of MassachusettsAllele-targeted rna interference
US20040175732A1 (en)*2002-11-152004-09-09Rana Tariq M.Identification of micrornas and their targets
WO2004050125A1 (ja)2002-12-032004-06-17Koken Co.,Ltd.腫瘍細胞の増殖及び／又は浸潤の抑制剤
EP1573009B1 (en)*2002-12-182011-09-21Third Wave Technologies, Inc.Detection of small nucleic acids
US7851150B2 (en)*2002-12-182010-12-14Third Wave Technologies, Inc.Detection of small nucleic acids
WO2004062487A2 (en)2003-01-132004-07-29Emory UniversityMethods of detecting gene expression in normal and cancerous cells
MXPA05007613A (es)2003-01-162005-09-30Univ North Carolina StateReduccion de celulas germinales primordiales endogenas en especies de aves.
WO2004066183A2 (en)*2003-01-222004-08-05European Molecular Biology LaboratoryMicrorna
US20040147027A1 (en)*2003-01-282004-07-29Troy Carol M.Complex for facilitating delivery of dsRNA into a cell and uses thereof
CA2515586A1 (en)2003-02-102004-09-10National Institute Of Advanced Industrial Science And TechnologyRegulation of gene expression by dna interference
US7816337B2 (en)2003-02-182010-10-19Roche Madison Inc.Reversible attachment of a membrane active polymer to a polynucleotide
US20040224337A1 (en)2003-03-042004-11-11Erik FoehrUse of biomolecular targets in the treatment and visualization of tumors
WO2004078941A2 (en)*2003-03-062004-09-16Oligo Engine, Inc.Modulation of gene expression using dna-rna hybrids
WO2004090108A2 (en)*2003-04-032004-10-21Alnylam PharmaceuticalsIrna conjugates
WO2004083816A2 (en)2003-03-142004-09-30John Wayne Cancer InstituteLoss of heterozygosity of the dna markers in the 12q22-23 region
WO2004086949A2 (en)2003-03-252004-10-14John Wayne Cancer InstituteDna markers for management of cancer
WO2004090105A2 (en)*2003-04-022004-10-21Dharmacon, Inc.Modified polynucleotides for use in rna interference
US20040198640A1 (en)2003-04-022004-10-07Dharmacon, Inc.Stabilized polynucleotides for use in RNA interference
US20040229211A1 (en)2003-05-132004-11-18Yeung Wah Hin AlexSensitive diagnostic testing methodology using multiplex real time PCR with one dye (MOD) and its use as in severe acute respiratory syndrome (SARS)
US7640114B2 (en)2003-05-212009-12-29The Wistar Institute Of Anatomy & BiologyMethod of diagnosis of cancer based on gene expression profiles in cells
US7459547B2 (en)2003-06-022008-12-02University Of MassachusettsMethods and compositions for controlling efficacy of RNA silencing
US7750144B2 (en)2003-06-022010-07-06University Of MassachusettsMethods and compositions for enhancing the efficacy and specificity of RNA silencing
US8309704B2 (en)2003-06-022012-11-13University Of MassachusettsMethods and compositions for enhancing the efficacy and specificity of RNAi
US20050059024A1 (en)2003-07-252005-03-17Ambion, Inc.Methods and compositions for isolating small RNA molecules
EP2530157B1 (en)*2003-07-312016-09-28Regulus Therapeutics Inc.Oligomeric compounds and compositions for use in modulation of miRNAs
US8106180B2 (en)*2003-08-072012-01-31Whitehead Institute For Biomedical ResearchMethods and products for expression of micro RNAs
US20050037362A1 (en)2003-08-112005-02-17Eppendorf Array Technologies, S.A.Detection and quantification of siRNA on microarrays
US20060183128A1 (en)2003-08-122006-08-17Epigenomics AgMethods and compositions for differentiating tissues for cell types using epigenetic markers
WO2005017145A1 (ja)2003-08-132005-02-24Japan Biological Informatics Consortium機能性ｒｎａが制御する被制御遺伝子の同定・予測方法及びその利用方法
KR20060125743A (ko)2003-11-102006-12-06녹손 파르마 아게생체 활성형 그렐린에 특이적으로 결합하는 핵산
US20050130172A1 (en)2003-12-162005-06-16Bayer CorporationIdentification and verification of methylation marker sequences
US20050130170A1 (en)2003-12-162005-06-16Jeanne HarveyIdentification and verification of methylation marker sequences
EP1713938A2 (en)2004-02-092006-10-25Thomas Jefferson UniversityDIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES
AU2005214904B2 (en)*2004-02-132011-07-21Rockefeller UniversityAnti-microRNA oligonucleotide molecules
US20050182005A1 (en)2004-02-132005-08-18Tuschl Thomas H.Anti-microRNA oligonucleotide molecules
KR100522307B1 (ko)*2004-02-192005-10-19변영철화장용브러시
US7402389B2 (en)2004-02-242008-07-22The Translational Genomics Research Institute (Tgen)Compositions and methods for prognosis of cancers
US20060195266A1 (en)2005-02-252006-08-31Yeatman Timothy JMethods for predicting cancer outcome and gene signatures for use therein
CA2561073C (en)*2004-03-272014-01-14The Arizona Board Of Regents On Behalf Of The University Of ArizonaComposition and method for cancer treatment
US20060134639A1 (en)*2004-04-062006-06-22Huffel Christophe VMethod for the determination of cellular transcriptional regulation
US7365058B2 (en)*2004-04-132008-04-29The Rockefeller UniversityMicroRNA and methods for inhibiting same
CN101056991A (zh)*2004-04-202007-10-17基因耐克生物医学制品有限公司检测ncRNA的方法
US7307067B2 (en)2004-05-042007-12-11The Board Of Trustees Of The Leland Stanford UniversityMethods and compositions for reducing viral genome amounts in a target cell
WO2005111211A2 (en)*2004-05-142005-11-24Rosetta Genomics Ltd.Micronas and uses thereof
WO2005116261A2 (en)2004-05-242005-12-08Albert Einstein College Of Medecine Of Yeshiva UniversityRna expression microarrays
EP2290068A3 (en)2004-05-282012-01-04Asuragen, Inc.Methods and compositions involving microRNA
US7575863B2 (en)2004-05-282009-08-18Applied Biosystems, LlcMethods, compositions, and kits comprising linker probes for quantifying polynucleotides
US20050287539A1 (en)2004-06-292005-12-29Emmanuel LabourierMethods and compositions for preparing capped RNA
AU2005328382C1 (en)2004-07-212013-01-24Alnylam Pharmaceuticals, Inc.Oligonucleotides comprising a modified or non-natural nucleobase
US7582744B2 (en)2004-08-102009-09-01Alnylam Pharmaceuticals, Inc.Chemically modified oligonucleotides
EP2338994B1 (en)2004-09-022014-03-19Yale UniversityRegulation of oncogenes by microRNAs
US20060057595A1 (en)2004-09-162006-03-16Applera CorporationCompositions, methods, and kits for identifying and quantitating small RNA molecules
US7642348B2 (en)2004-10-042010-01-05Rosetta Genomics LtdProstate cancer-related nucleic acids
US7825229B2 (en)2005-03-252010-11-02Rosetta Genomics Ltd.Lung cancer-related nucleic acids
US7592441B2 (en)2004-10-042009-09-22Rosetta Genomics LtdLiver cancer-related nucleic acids
US20090186353A1 (en)2004-10-042009-07-23Rosetta Genomics Ltd.Cancer-related nucleic acids
US20060134661A1 (en)2004-10-122006-06-22Richard EssnerTreatment of cancer and compositions
US20060078894A1 (en)*2004-10-122006-04-13Winkler Matthew MMethods and compositions for analyzing nucleic acids
FR2877350B1 (fr)*2004-11-032010-08-27Centre Nat Rech ScientIDENTIFICATION ET UTILISATION DE miRNAs IMPLIQUES DANS LA DIFFERENCIATION DE CELLULES ISSUES D'UNE LEUCEMIE MYELOIDE
EP2284265B1 (en)2004-11-122015-01-07Asuragen, Inc.Methods and compositions involving miRNA and miRNA inhibitor molecules
US7074622B2 (en)*2004-11-152006-07-11Eastman Kodak CompanyMethod and system for sorting and separating particles
WO2006060653A2 (en)2004-11-302006-06-08Veridex LlcLung cancer prognostics
US20060154275A1 (en)2004-12-022006-07-13The Board Of Trustees Of The Leland Stanford Junior UniversityRegulated genes in cervical cancer
US20060185027A1 (en)2004-12-232006-08-17David BartelSystems and methods for identifying miRNA targets and for altering miRNA and target expression
US20070099196A1 (en)*2004-12-292007-05-03Sakari KauppinenNovel oligonucleotide compositions and probe sequences useful for detection and analysis of micrornas and their target mRNAs
WO2006113679A2 (en)2005-04-152006-10-26Board Of Regents, The University Of Texas SystemDelivery of sirna by neutral lipid compositions
AU2006211960A1 (en)*2005-02-082006-08-17Board Of Regents, The University Of Texas SystemCompositions and methods involving MDA-7 for the treatment of cancer
US7495073B2 (en)*2005-03-242009-02-24Asia Hepato Gene CompanyShort isoform of Annexin A10 at chromosome 4q, termed Annexin 10s (ANXA10s) and methods of use
US20090062184A1 (en)2005-03-242009-03-05Dainippon Sumitomo Pharma Co., Ltd.Fine particulate preparation comprising complex of nucleic acid molecule and collagen
GB2425311A (en)*2005-04-152006-10-25Ist Superiore SanitaMicro RNA against kit protein
JP2008539731A (ja)2005-05-022008-11-20コールド スプリング ハーバー ラボラトリー癌の診断及び治療のための組成物及び方法
US20070072201A1 (en)*2005-05-162007-03-29Kohne David EMethod for producing improved nucleic acid oligomer functional homogeneity and functional characteristic information and results and oligomer application results
US20060265771A1 (en)*2005-05-172006-11-23Lewis David LMonitoring microrna expression and function
GB0601102D0 (en)*2006-01-192006-03-01Nuclea Biomarkers LlcKinase Peptides And Antibodies
US20070054287A1 (en)*2005-05-312007-03-08Applera CorporationMethod for identifying medically important cell populations using micro rna as tissue specific biomarkers
WO2006128245A1 (en)2005-06-032006-12-07Southern Adelaide Health Service-Flinders Medical CentreTargeting cells with altered microrna expression
US20070065844A1 (en)*2005-06-082007-03-22Massachusetts Institute Of TechnologySolution-based methods for RNA expression profiling
CA2611507A1 (en)*2005-06-092006-12-21Epoch Biosciences, Inc.Improved primer-based amplification methods
US20060292616A1 (en)2005-06-232006-12-28U.S. Genomics, Inc.Single molecule miRNA-based disease diagnostic methods
KR101140575B1 (ko)*2005-06-302012-05-02엘지디스플레이 주식회사액정표시장치 검사공정
CN103820562B (zh)2005-08-012015-05-13俄亥俄州立大学研究基金会用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物
IL177006A0 (en)2005-08-022006-12-10Veridex LlcPredicting bone relapse of breast cancer
US20070213292A1 (en)2005-08-102007-09-13The Rockefeller UniversityChemically modified oligonucleotides for use in modulating micro RNA and uses thereof
US20070041934A1 (en)2005-08-122007-02-22Regents Of The University Of MichiganDendrimer based compositions and methods of using the same
WO2007033023A2 (en)2005-09-122007-03-22The Ohio State University Research FoundationCompositions and methods for the diagnosis and therapy of bcl2-associated cancers
WO2007056232A2 (en)2005-11-042007-05-18Merck & Co., Inc.Methods of using saha and bortezomib for treating cancer
US7390792B2 (en)2005-12-152008-06-24Board Of Regents, The University Of Texas SystemMicroRNA1 therapies
WO2007087113A2 (en)2005-12-282007-08-02The Scripps Research InstituteNatural antisense and non-coding rna transcripts as drug targets
US20100286044A1 (en)2005-12-292010-11-11Exiqon A/SDetection of tissue origin of cancer
WO2007081680A2 (en)2006-01-052007-07-19The Ohio State University Research FoundationMicrorna expression abnormalities in pancreatic endocrine and acinar tumors
EP2487258B1 (en)2006-01-052014-10-01The Ohio State University Research FoundationMicroRNA-based methods for the diagnosis of colon, pancreas and stomach cancer
CA2633674A1 (en)2006-01-052007-07-19The Ohio State University Research FoundationMicrorna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
WO2007087451A2 (en)2006-01-252007-08-02University Of MassachusettsCompositions and methods for enhancing discriminatory rna interference
US8129515B2 (en)2006-01-272012-03-06Isis Pharmaceuticals, Inc.Oligomeric compounds and compositions for the use in modulation of microRNAs
EP2522750A1 (en)2006-03-022012-11-14The Ohio State UniversityMicroRNA expression profile associated with pancreatic cancer
US7955848B2 (en)2006-04-032011-06-07Trustees Of Dartmouth CollegeMicroRNA biomarkers for human breast and lung cancer
EP2047864B1 (en)*2006-06-162017-04-05Taisho Pharmaceutical Co., Ltd.Use of rpn2 gene expression inhibitor
US20080076674A1 (en)*2006-07-062008-03-27Thomas LitmanNovel oligonucleotide compositions and probe sequences useful for detection and analysis of non coding RNAs associated with cancer
EP2436783B1 (en)2006-07-132013-09-11The Ohio State University Research FoundationMIR-103-2 for diagnosing poor survival prognosis colon adenocarcinoma.
US8466117B2 (en)2006-07-282013-06-18The Johns Hopkins UniversityCompositions and methods for modulating angiogenesis
EP2145001A2 (en)2006-09-192010-01-20Asuragen, Inc.Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
EP2487240B1 (en)*2006-09-192016-11-16Interpace Diagnostics, LLCMicrornas differentially expressed in pancreatic diseases and uses thereof
JP2010504350A (ja)2006-09-192010-02-12アシュラジェン インコーポレイテッド治療的介入の標的としての、ｍｉＲ−２００によって調節される遺伝子および経路
US20080131878A1 (en)*2006-12-052008-06-05Asuragen, Inc.Compositions and Methods for the Detection of Small RNA
WO2008073915A2 (en)*2006-12-082008-06-19Asuragen, Inc.Micrornas differentially expressed in leukemia and uses thereof
CA2671194A1 (en)2006-12-082008-06-19Asuragen, Inc.Mir-20 regulated genes and pathways as targets for therapeutic intervention
DK2104737T3 (da)2006-12-082013-05-27Asuragen IncFunktioner og formål for let-7 mikro-RNAer
EP2104735A2 (en)2006-12-082009-09-30Asuragen, INC.Mir-21 regulated genes and pathways as targets for therapeutic intervention
CA2671270A1 (en)2006-12-292008-07-17Asuragen, Inc.Mir-16 regulated genes and pathways as targets for therapeutic intervention
WO2008088858A2 (en)2007-01-172008-07-24The Johns Hopkins UniversityCompositions and methods featuring micronas for treating neoplasia
WO2008092099A2 (en)2007-01-262008-07-31Rosetta Genomics, Ltd.Compositions and methods for treating hematopoietic malignancies
WO2008095096A2 (en)2007-01-312008-08-07Immune Disease InstituteLet-7 microrna and mimetics thereof as therapeutics for cancer
EP2147122B1 (en)2007-04-202014-07-16Sigma-Tau Rare Diseases S.A.Enzymatic anticancer therapy
CA2685840C (en)2007-04-302016-12-13The Ohio State University Research FoundationMethods for differentiating pancreatic cancer from normal pancreatic function and/or chronic pancreatitis
JP2010525826A (ja)*2007-05-032010-07-29ロゼッタ インファーマティックス エルエルシー癌を治療するためのｍｉｒ３４治療剤を含む組成物
US20090131354A1 (en)*2007-05-222009-05-21Bader Andreas GmiR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090232893A1 (en)2007-05-222009-09-17Bader Andreas GmiR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090227533A1 (en)2007-06-082009-09-10Bader Andreas GmiR-34 Regulated Genes and Pathways as Targets for Therapeutic Intervention
US7993831B2 (en)2007-09-142011-08-09Asuragen, Inc.Methods of normalization in microRNA detection assays
WO2009036332A1 (en)2007-09-142009-03-19Asuragen, Inc.Micrornas differentially expressed in cervical cancer and uses thereof
WO2009052386A1 (en)2007-10-182009-04-23Asuragen, Inc.Micrornas differentially expressed in lung diseases and uses thereof
AU2008318778B2 (en)2007-10-292014-10-02Regulus Therapeutics Inc.Targeting microRNAs for the treatment of liver cancer
US8071562B2 (en)*2007-12-012011-12-06Mirna Therapeutics, Inc.MiR-124 regulated genes and pathways as targets for therapeutic intervention
WO2009075787A1 (en)*2007-12-052009-06-18The Johns Hopkins UniversityCompositions and methods of treating neoplasia
US20090192114A1 (en)2007-12-212009-07-30Dmitriy OvcharenkomiR-10 Regulated Genes and Pathways as Targets for Therapeutic Intervention
US20090263803A1 (en)2008-02-082009-10-22Sylvie BeaudenonMirnas differentially expressed in lymph nodes from cancer patients
EP2096171A1 (en)*2008-02-272009-09-02Julius-Maximilians-Universität WürzburgMicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
EP2254668A4 (en)2008-02-282012-08-15Univ Ohio State Res Found MICROARN SIGNATURES ASSOCIATED WITH HUMAN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND USES THEREOF
US20090233297A1 (en)2008-03-062009-09-17Elizabeth MamboMicrorna markers for recurrence of colorectal cancer
EP2268811A1 (en)*2008-03-072011-01-05Santaris Pharma A/SPharmaceutical compositions for treatment of microrna related diseases
US20090253780A1 (en)2008-03-262009-10-08Fumitaka TakeshitaCOMPOSITIONS AND METHODS RELATED TO miR-16 AND THERAPY OF PROSTATE CANCER
WO2009126726A1 (en)2008-04-082009-10-15Asuragen, IncMethods and compositions for diagnosing and modulating human papillomavirus (hpv)
EP2990487A1 (en)2008-05-082016-03-02Asuragen, INC.Compositions and methods related to mirna modulation of neovascularization or angiogenesis
CN102112110A (zh)2008-06-062011-06-29米尔纳医疗股份有限公司用于RNAi试剂体内递送的新型组合物
US20100090959A1 (en)2008-10-142010-04-15Sony Ericsson Mobile Communications AbForming a keyboard from a combination of keys displayed on a touch sensitive display and on a separate keypad
US20100179213A1 (en)2008-11-112010-07-15Mirna Therapeutics, Inc.Methods and Compositions Involving miRNAs In Cancer Stem Cells
US8492133B2 (en)*2009-01-202013-07-23Ramot At Tel Aviv University, Ltd.MIR-21 promoter driven targeted cancer therapy
US7665785B1 (en)2009-04-082010-02-23Newton Paul AColumn pipe catch tool
US8778903B2 (en)*2009-10-212014-07-15Trustees Of Dartmouth CollegeMicroRNA-10 antagonists and MicroRNA-10 targets for use in the treatment of a glioma
US8841273B2 (en)2009-10-282014-09-23Board Of Regents, The University Of Texas SystemMethods and compositions for anti-EGFR treatment
CA2781547A1 (en)2009-11-232011-05-26The Ohio State UniversityMaterials and methods useful for affecting tumor cell growth, migration and invasion
EP2504014A4 (en)2009-11-242013-04-17Univ Western Australia MODULATION OF EPIDERMAL GROWTH FACTOR RECEPTOR LIGANDS
US8846631B2 (en)2010-01-142014-09-30Regulus Therapeutics Inc.MicroRNA compositions and methods
US8933051B2 (en)2010-09-302015-01-13University Of ZurichTreatment of B-cell lymphoma with microRNA
CN103459598B (zh)*2011-02-032016-08-10米尔纳医疗股份有限公司Mir-124的合成模拟物
MX342927B (es)*2011-02-032016-10-19Mirna Therapeutics IncMimeticos sinteticos de mir-34.
WO2012135728A1 (en)2011-03-302012-10-04University Of Louisville Research Foundation, Inc.Catalytic isomerisation of linear olefinic hydrocarbons
ES2868950T3 (es)2011-04-252021-10-22Sanofi SaCompuestos de microARN y métodos para modular la actividad de miR-21
CA2858382A1 (en)2011-12-102013-06-13Ohio State Innovation FoundationMirnas useful to reduce lung cancer tumorigenesis and chemotherapy resistance and related compositons and methods
UA116639C2 (uk)2012-10-092018-04-25Рег'Юлес Терап'Ютікс Інк.Способи лікування синдрому альпорта
CA2903882A1 (en)2013-03-152014-09-18Mirna Therapeutics, Inc.Combination cancer treatments utilizing micrornas and egfr-tki inhibitors
EP3013975A1 (en)2013-06-242016-05-04Mirna Therapeutics, Inc.Biomarkers of mir-34 activity
US20160136181A1 (en)2014-04-012016-05-19Mirna Therapeutics, IncMicrorna dosing regimens

Also Published As

Publication numberPublication date
JP2014217386A (ja)2014-11-20
CA2857879A1 (en)2006-12-28
US20150284720A1 (en)2015-10-08
EP2302052A1 (en)2011-03-30
ES2534303T3 (es)2015-04-21
JP2014012020A (ja)2014-01-23
EP2808390A1 (en)2014-12-03
ES2503738T3 (es)2014-10-07
ES2503739T3 (es)2014-10-07
US20090176723A1 (en)2009-07-09
US20150342981A1 (en)2015-12-03
EP2281886A1 (en)2011-02-09
EP2292756A1 (en)2011-03-09
EP2302053A1 (en)2011-03-30
CA2857880A1 (en)2006-12-28
PL2302055T3 (pl)2015-02-27
US8058250B2 (en)2011-11-15
EP2284265B1 (en)2015-01-07
US9068219B2 (en)2015-06-30
US20140348908A1 (en)2014-11-27
US20110313025A1 (en)2011-12-22
JP2014217387A (ja)2014-11-20
EP2281888A1 (en)2011-02-09
US9382537B2 (en)2016-07-05
SI2302055T1 (sl)2015-01-30
JP2016165292A (ja)2016-09-15
US9051571B2 (en)2015-06-09
US7960359B2 (en)2011-06-14
EP2302052B1 (en)2015-01-07
EP2302055A1 (en)2011-03-30
EP2302051A1 (en)2011-03-30
CA2857878A1 (en)2006-12-28
US20140348907A1 (en)2014-11-27
EP2281888B1 (en)2015-01-07
EP2284265A1 (en)2011-02-16
US20150299705A1 (en)2015-10-22
US20120065248A1 (en)2012-03-15
EP2302056B1 (en)2015-01-07
US20140314833A1 (en)2014-10-23
CA2857901A1 (en)2006-12-28
US20150344883A1 (en)2015-12-03
US20150352046A1 (en)2015-12-10
WO2006137941A3 (en)2008-01-03
JP5389690B2 (ja)2014-01-15
US20130303591A1 (en)2013-11-14
JP5620556B2 (ja)2014-11-05
ES2534302T3 (es)2015-04-21
ES2503742T3 (es)2014-10-07
CA2850323A1 (en)2006-12-28
EP2302054B1 (en)2014-07-16
ES2503741T3 (es)2014-10-07
ES2507544T3 (es)2014-10-15
EP2302051B1 (en)2015-01-07
EP2298894B1 (en)2014-07-16
EP2314688B1 (en)2014-07-16
US9447414B2 (en)2016-09-20
US20150004221A1 (en)2015-01-01
HK1204656A1 (en)2015-11-27
US8946177B2 (en)2015-02-03
ES2534300T3 (es)2015-04-21
EP2287303B1 (en)2014-07-02
US20170037404A1 (en)2017-02-09
US8563708B2 (en)2013-10-22
CA2857881A1 (en)2006-12-28
CA2587189A1 (en)2006-12-28
EP2808389A1 (en)2014-12-03
US20150005366A1 (en)2015-01-01
AU2005333165A1 (en)2006-12-28
EP2281889B1 (en)2014-07-30
ES2503765T3 (es)2014-10-07
EP2292756B1 (en)2014-07-16
US20140350086A1 (en)2014-11-27
US20150275213A1 (en)2015-10-01
EP2302055B1 (en)2014-08-27
EP2298893A1 (en)2011-03-23
US20150284719A1 (en)2015-10-08
US9506061B2 (en)2016-11-29
WO2006137941A9 (en)2007-03-08
ES2534301T3 (es)2015-04-21
EP2322616A1 (en)2011-05-18
JP5596085B2 (ja)2014-09-24
US20140031415A1 (en)2014-01-30
EP2287303A1 (en)2011-02-23
ES2534304T3 (es)2015-04-21
US20150344881A1 (en)2015-12-03
US20080176766A1 (en)2008-07-24
EP2314688A1 (en)2011-04-27
US8173611B2 (en)2012-05-08
US20080171715A1 (en)2008-07-17
DK2302055T3 (da)2014-10-13
JP2014223080A (ja)2014-12-04
EP2302056A1 (en)2011-03-30
EP2302054A1 (en)2011-03-30
US20130143945A1 (en)2013-06-06
AU2005333165B2 (en)2012-07-19
JP2010178741A (ja)2010-08-19
EP2281886B1 (en)2014-07-16
US8765709B2 (en)2014-07-01
EP2298894A1 (en)2011-03-23
EP1838852A2 (en)2007-10-03
EP2292755A1 (en)2011-03-09
JP2014217384A (ja)2014-11-20
JP2008519606A (ja)2008-06-12
US20150361431A1 (en)2015-12-17
ES2503740T3 (es)2014-10-07
EP2281887A1 (en)2011-02-09
EP2281889A1 (en)2011-02-09
US20080050744A1 (en)2008-02-28
JP2012228254A (ja)2012-11-22
JP2014217385A (ja)2014-11-20
JP2014217381A (ja)2014-11-20
WO2006137941A2 (en)2006-12-28

Similar Documents

PublicationPublication DateTitle
ES2503743T3 (es)Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
JP2010539959A5 (es)
US9353368B2 (en)Micro-RNA scaffolds and non-naturally occurring micro-RNAs
JP5902088B2 (ja)マイクロｒｎａの製造方法およびその治療的応用
US20110151430A1 (en)VIRUS-SPECIFIC miRNA SIGNATURES FOR DIAGNOSIS AND THERAPEUTIC TREATMENT OF VIRAL INFECTION
US11041201B2 (en)Methods for detection of RNase activity
JP2020536554A5 (es)
CN103476947A (zh)寡聚体的增强的生物分布
US8859239B2 (en)Methods for small RNA sequencing
NM_205822 et al.Supplementary Table
Efimenko et al.Data supporting that miR-92a suppresses angiogenic activity of adipose-derived mesenchymal stromal cells by down-regulating hepatocyte growth factor
EP3862442A2 (en)Method for the early diagnosis of cancer by means of ddpcr analysis of mirna in liquid biopsy
OmnibusAUC: area under curve. KEGG: Kyoto Encyclopedia of Genes and Genomes. GEO: Gene
WO2024104396A1 (zh)一种使用miRNA亚型相对家族占比检测癌症等疾病的方法
LUAD17 hsa-mir-222 88.23 Table S1: List of miRNAs returned from at least one run of the DE algorithm. The list is sorted according to decreasing number of times it has been reported. The value of the k-esim row refears to the classification accuracy obtained using the subset of the first k miRNAs.
[8]ページ先頭
©2009-2025 Movatter.jp